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Regarding the recent outbreak of Zika virus (ZIKV) infection, there is an urgent need to develop a 
preventive or a therapeutic ZIKV vaccine. In this thesis, computational analysis was performed to 
predict suitable peptide candidates for vaccine design. 
Computational approaches such as docking and molecular dynamics simulations (MD 
simulations) were employed to evaluate the binding energy and stability of candidate T-cell 
epitope peptides of ZIKV proteins at the antigen-presenting MHC class I molecules. For the 
docking step and the following MD simulations, MHC I alleles HLA-A*0101, HLA-A*0201, HLA-
B*2705 and HLA-C*0801 were used as receptor structures and eight different peptides from ZIKV 
proteins (E, NS3, NS5) were docked to the MHC I molecules. 
All predicted peptide-HLA complexes and experimental reference peptide-HLA complexes 
were submitted to a 10-ns MD simulation in explicit water for further refinement and to examine 
and compare their stability. Hydrogen bonding network, Root-Mean-Square Deviation (RMSD) 
for both the MHC I peptide-binding domain and the peptides, atomic fluctuation and solvent 
accessibility of the bound peptides, interaction energies and the dimensions of the peptide 
binding groove were analyzed to evaluate the stability and strength of the peptide-HLA 
complexes. 
The computational analysis provided two T-cell epitopes from the ZIKV proteins 
(GLDFSDLYY, FSDLYYLTM) with a high affinity to the studied MHC I alleles. These could be 
introduced as putative candidates for vaccine development. 
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Viruses are highly dependent upon their target host cell for replication. This means that, based 
on the type of virus, DNA or RNA, they assemble their genome in the host cell nucleus or 
cytoplasm, respectively.  
Zika virus (ZIKV) belongs to the Flaviviridae family that has a single-stranded RNA genome. 
Its genome encodes a polyprotein comprised of seven non-structural, namely, NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, NS5 and three structural proteins: capsid (C), premembrane/membrane protein 
(PrM/M) and envelope (E) protein (Lindenbach & Rice, 2003; Mirza et al., 2016 ). The virus was 
isolated in 1940 from a Ugandan forest where its name comes from (Dick et al., 1952). Monkeys 
were the primary vertebrate host for the virus (Fauci & Morens, 2016). 
There are several ways of virus transmission such as Mosquito bites, sexual contacts, 
pregnancy and blood transfusion (Mansuy et al., 2016). During pregnancy, the virus can transmit 
transplacentally to the fetus and lead to several adverse outcomes such as congenital 
microcephaly, malformation and miscarriage (Brasil et al., 2016; Malkar et al., 2016), as well as 
ocular lesion in surviving infants (de Paula Freitas et al., 2016; Ventura et al., 2016). 
There was an epidemic outbreak caused by ZIKV during 2007-2016 across the Pacific 
Ocean. The adverse complexities of the disease, especially the teratogenic lesions, demand 
urgent action to develop a vaccine against the infection (Oehler et al., 2014). 
It has been shown that the identification of antigenic epitopes recognized by T-cells and 
B-cells is the first and most significant step to design a vaccine since a component of immune 
system, such as T-cell as a mediator, could be stimulated via such epitopes (Backert & Kohlbacher, 
2015). Identifying these epitopes has been possible using immunoinformatics methods (Florea et 
al., 2003). It has also been suggested that the degree of elicited T-cell response is highly correlated 
to the strength of binding between the epitope and the MHC molecule (Lazarski et al., 2005; Liu 
et al., 2010). This study employed peptide docking and molecular dynamics (MD) simulation 




2. Literature review 
 
2.1 MHC I molecules 
 
Proteins are substantial macromolecules that play vital roles in living systems and many biological 
processes. They are polymers consisting of monomers called amino acids. Based on the 
characteristics of amino acids, a protein has a broad range of functional properties which allow it 
to fold and adapt different conformations from linear or primary structure to quaternary 
structure (National Research Council, 1989). Regarding the important role of proteins in living 
systems, it is of great importance to access the three-dimensional (3D) structure of proteins. 
There are two commonly used experimental methods that are capable in solving high-resolution 
3D structures of proteins: X-ray crystallography and NMR spectroscopy.  
The proteins that are studied in this project are called major histocompatibility complex (MHC) 
molecules. Many MHC structures have been determined with X-ray crystallography. Due to the 
major effects that these molecules have on the histocompatibility, they were called major 
histocompatibility molecules. 
The MHC genes are divided into three different classes according to their locations, 
namely classes I, II, and III (Abbas et al., 2014). MHC class I (MHC I) genes are present on 
chromosome 6 in humans and they are known as Human Leukocyte Antigens (HLAs). They are 
coded at three different locations (loci) on the genome named A, B and C. MHC molecules are 
found on all the nucleated cells in the body, and they play an important role in the development 
of both humoral and cellular immunity. T-cells (cellular immunity) recognize antigens only as 
peptides that are bound to a MHC I molecule. The main function of MHC I molecules is to bring 
antigens to the cell surface for recognition by a T-cell. An antigenic peptide binds to the MHC 
molecule with high affinity to make a stable complex. 
Of the three existing types of human MHC molecules, we focus on the MHC class I molecules. 
MHC I molecules are cell surface glycoproteins and key actors in the process of adaptive immunity. 
They are on the surface of antigen-presenting cells (APCs). They bind to peptides ranging from 
eight to ten residues and are recognized by CD8+ cytotoxic T lymphocytes. The antigenic peptides 
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presented by MHC I can be from pathogens such as viruses that are to be destructed by CD8+ T-
cells. The MHC I pathway is shown in Figure 1. 
 
 
Figure 1. Cytosolic pathway of MHC I. Source: Scray, MHC Class I processing, CC BY-SA 3.0. 
 
MHC I molecules are heterodimeric transmembrane proteins that consist of a single α 
chain that is coupled with the β2 microglobulin protein (Figure 2A). The α chain has been divided 
into three different parts, namely α1, α2, and α3. The α1 and α2 segments build the wall of the 
peptide-binding groove while eight antiparallel β-stranded sheets create the floor of the groove. 
This structure is known as α1α2 domain (Figure 2B). α3 domain is located in the membrane and 
it is the region where MHC I interacts with the CD8+ molecule (Toh et al., 2000). The α chain (270 
amino acid residues) is polymorphic and encoded by HLA genes, whereas β2 microglobulin 




Figure 2. Cartoon representation of the MHC class I protein visualized with Chimera (Pettersen et al., 2004) (PDB ID: 
5SWQ). A: The arrangement of α domains (tan color) and β2 microglobulin (β2M) domain (green color); black box 
denotes the peptide-binding groove. B: Top view of the peptide-binding groove. 
 
As depicted in Figure 3, the peptide anchor residues to be buried in the peptide-binding groove 
of the MHC I molecule are at position 2 (P2) and 9 (P9). Positions 4 to 7 (P4-P7) are usually T-cell 
binders (Brown JH, 1993; Falk et al., 1991; Hunt et al., 1992; Stern et al., 1994 ). The geometry, 
charge distribution, and hydrophobicity of the binding groove determine the type of interaction 





Figure 3.  A stick model of a nonapeptide (yellow) binding to the MHC I molecule, HLA-A*0201; PDB ID: 5SWQ (surface 
representation). The subpockets are labeled from A to F. The main anchor residues (P2, P9) are deeply buried into 
the B and F subpockets, respectively. T-cell-receptor-binding residues (P4, P6 and P8) are labeled in red. P1, P5 and 
P7 side chains may bind both the MHC I groove and the T-cell receptor. Visualization with Chimera v. 1.13 (Pettersen 
et al., 2004) using the hydrophobicity scale of Kyte & Doolittle (1982): Hydrophobicity property from blue for the 
most hydrophilic, to white for intermediate hydrophobicity, to orange-red for the most hydrophobic. 
A              B     C 
 
Figure 4. The MHC I peptide-binding groove properties determine the type of interactions formed with the peptide 
side chains. Top view; visualization with Chimera v. 1.13.1, PDB ID: 5SWQ. A: Molecular electrostatic potential 
(Coulombic surface coloring: blue for positive potential, white for neutral potential and red for negative potential). 
B: Hydrophobicity property from blue for the most hydrophilic, to white for intermediate hydrophobicity, to orange-
red for the most hydrophobic (kdHydrophobicity scale) (Kyte, & Doolittle, 1982). C: B-factor distribution; the lowest 
B-factors (blue color) are in the MHC I groove core, peptide N-terminus (P1-P3) and C-terminus (P8 and P9) and the 
highest B factor (red color) is seen in the middle positions (P4-P7) of the peptide residues. 
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2.2 Vaccine development 
 
Since viruses have multiple mechanisms to evade the host's immune response and exhibit 
diversity in their genes, a good approach for production of vaccines that stimulate T-cells is using 
highly conserved proteins of viruses as candidates (Rosendahl et al., 2014). 
In recent years, bioinformatics has had a vital role in drug and vaccine design and 
development (Soria-Guerra et al., 2015). One goal of bioinformatics is to extract essential 
knowledge from genome, transcriptome and proteome to advance health issues (Brusic & Flower, 
2004). Vaccine design by bioinformatics is more convenient, safer and less expensive than by 
earlier conventional approaches (Soria-Guerra et al., 2015).   
The first demonstration of efficacy of a peptide vaccine containing a 15-mer peptide was 
published by Aichele et al. (1990). There is now a wide range of bioinformatics tools that are 
helpful for the prediction of novel T-cell epitopes based on the peptide anchor-residue binding 
positions in the MHC molecules (Adamczyk-Poplawska et al., 2011). Currently, it is well-
established that T-cell epitopes interact with the MHC I binding groove in a linear mode (Aichele 
et al., 1990; Falk et al., 1991). This insightful concept inspired to develop a large number of 
algorithms to identify T-cell epitopes (DeLisi & Berzofsky, 1985; McMurry et al., 2005). Rosalia and 
co-workers (2013) showed that longer peptides result in enhanced CD8+ T-cell activation. CD8+ 
T-cells are the principal agents that clear the virus-infected cells (Rosalia et al., 2013). 
There are antiviral drugs for the treatment of viral infectious diseases. However, viruses 
might escape such treatment by a mutation in their protein structure, which in turn leads to 
resistance against anti-viral drugs. To combat this challenge, activation and stimulation of host 
immune system can be an alternative CD4+ T helper cell and CD8+ cytotoxic T-cell response. The 
most notable advantage of peptide vaccines over protein and live attenuated vaccines is their 
flexibility to match escape variants. As mentioned earlier, mutation is a mechanism by which a 
virus can escape from the host immune system. Peptide vaccines are also safe and easy to 
produce. Nevertheless, choosing the right epitopes and avoiding the overstimulation of immune 
response is of great importance to be noted (Rosendahl et al., 2014).approach (Rosendahl et al., 
2014). There are plenty of antibody-mediated vaccines which are, however, beneficial only in the 
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preventive stage of a viral infection since after the cells are infected only cellular immune 
response can eliminate the infection. This can be achieved by T-cell based vaccination. There are 
several types of T-cell-based vaccines, i.e. protein vaccines, live attenuated vaccines and peptide 
vaccines. Peptide vaccines are entirely synthetic, and they are composed of small protein 
fragments, peptides. Based on the included peptides, they may also be capable of inducing 
humoral response which stimulates both  
 
2.3 General Principles in Rational Drug Design 
 
There are generally two major requirements we need to achieve in order to be able to proceed 
in rational drug design. First, we need to understand the normal human physiology and pathology 
and also how the physiological/pathological pathways are regulated. This will help in mapping 
and identifying the target steps and molecules involved in the case of a disease. Second, we need 
knowledge about the 3D structure of the target molecule and/or its ligands. For structure-based 
drug design (direct design) there must exist knowledge about the target molecule and for ligand-
based drug design (indirect design) (Tollenaere, 1996) there must exist knowledge about the 
molecules that bind to the target (Liljefors  et al., 2002; Merz et al., 2010). Finally, after obtaining 
this knowledge and knowing about the disease at the molecular level, a drug can be designed to 
interact with the target to prevent or interrupt the disease. For this study, all requirements for 
rational design have been met (desired physiological effect: T-cell response against ZIKV virus; 






The overall aim of this study was to identify appropriate T-cell epitope candidates from Zika virus 
for the development of vaccine design using in silico techniques. 
The specific aims were to: 
 Evaluate sequence conservation among human MHC I molecules via sequence analysis.  
 Evaluate the binding interactions inside the peptide-binding groove of the experimentally 
determined peptide-MHC I structures. 
 Study the binding interactions in docked peptide-MHC I complexes in light of the binding 
interactions from known crystal complexes. 
 Estimate the peptide binding affinity according to the peptide binding interactions. 





4. Materials and Methods 
 
4.1 Ligands: Selection of potential antigenic peptides from ZIKV proteins 
 
Mirza and co-workers (2016) predicted potential antigenic T-cell epitopes from three ZIKV 
proteins, namely E, NS3 and NS5 by employing the NetCTL-1.2 server (Larsen et al., 2007). In this 
study, eight epitopes from the total identified potential T-cell epitopes have been randomly 
selected for detailed binding interaction studies (Tables 1A-C).  
 
Table 1A. Predicted T-cell epitopes from ZIKV E proteins (Mirza et al., 2016). 
 
*NetCTL-1.2 prediction score threshold >0.75000. The epitopes GLDFSDLYY and TMNNKHWLV were selected to dock 
to MHC I HLA-A*0101 and the epitopes MAEVRSYCY and FSDLYYLTM were selected to dock to MHC I HLA-A*0201. 




Table 1B. Predicted T-cell epitopes from ZIKV NS3 proteins (Mirza et al., 2016).
 
*NetCTL-1.2 prediction score threshold >0.75000. The colored epitopes were selected to dock to MHC I HLA-B*2705. 
Colors are in line with the resulting graphs in Chapter 5. 
 
Table 1C. Predicted T-cell epitopes from ZIKV NS5 proteins (Mirza et al., 2016). 
 
*NetCTL-1.2 prediction score threshold >0.75000. The colored epitopes were selected to dock to MHC I HLA-C*0801 




4.2 Targets: Selection of MHC I molecules 
 
As mentioned earlier, one of the key things in drug design is the selection of the target molecule 
and obtaining its 3D structure. The Protein Data Bank (PDB, http://www.rcsb.org/; Berman et al., 
2000) is a freely accessible public database storing 3D structural data of biological 
macromolecules such as proteins and nucleic acids. PDB was used to retrieve the 3D structures 
of our target MHC I molecules that were selected following the work of Mirza et al (2016). The X-
ray crystal structures of MHC I types HLA-A*0101, HLA-A*0201, HLA-B*2705 and HLA-C*0801 
with the resolution of less than 2.5 Å were retrieved from PDB. Through superimposing all 
retrieved experimentally determined structures, eleven complexes following the common MHC 
I-peptide complex pattern were totally selected for this study: one structure for HLA-A*0101 (PDB 
ID: 4NQV) (N.B. this MHC I type was not studied in Mirza et al., 2016), eight structures for HLA-
A*0201 (PDB IDs: 1OGA, 2GIT, 2GTW, 2GTZ, 3I6G, 3TO2, 4K7F and 5SWQ), one structure for HLA-
B*2705 (PSB ID: 2BST) and one structure for HLA-C*0801 (PDB ID: 4NT6). The reason for studying 
eight different crystal structures of the MHC I HLA-A*0201 molecule was to map any possible 
consensus interactions that are always present when an antigenic peptide binds to that HLA type. 
This step was performed with Chimera v. 1.13.1, a molecular graphics tool developed by UCSF 
(http://www.rbvi.ucsf.edu/chimera) (Pettersen et al., 2004). 
 
4.3 Amino Acid Sequence Retrieval 
 
For the amino acid sequence analysis of the MHC-I molecules, the selected types of HLA 
sequences were obtained from the UniProt database (The UniProt Consortium, 2017, 
http://www.uniprot.org/; HLA-A*0101: P30443.1|HLA-A-1; HLA-A*0201: P01892.1|HLA-A-2; 
HLA-B*2705: P03989.2|HLA-B-27; HLA-C*0801: P30505.1|HLA-Cw-8) and stored in FASTA 
format. UniProt is a database containing information about the sequence and function of proteins 
(Chen et al., 2017). FASTA is a text-based format to represent nucleotide or peptide sequences in 
single-letter code (Lipman & Pearson, 1985). The sequence header starts with a greater-than (>) 
symbol. 
Next, we looked for homologous HLA proteins for each selected MHC I protein in the 
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SwissProt database within UniProt. Accordingly, five homologs with an identity percent ranging 
from 70 to 95 percent for HLA-A*0101 and HLA-A*0201  types,  six homologs for HLA-B*2705 and  
five homologs for HLA-C*0801 with the same range of identity percent were selected with the 
Basic Local Alignment Search Tool (BLAST, https://www.ncbi.nlm.nih.gov/BLAST/; Altschul et al. 
1990). BLAST is one of the most used heuristic sequence searching algorithms in bioinformatics 
(it is heuristic in speeding up the computational process for a considerable amount of data) for 
finding high-scoring sequences among related sequences in a sequence database. Figure 5 
presents the selected parameters for ‘blasting’. 
  





The next step was to perform a Multiple Sequence Alignment (MSA) of these twenty 
homologous sequences: 
P30443.1|HLA-A-1  P03989.2|HLA-B-27  P30505.1|HLA-Cw-8 
P01892.1|HLA-A-2  P01889.3|HLA-B-7  P30499.1|HLA-Cw-1 
P04439.2|HLA-A-3   P30460.1|HLA-B-8  P30501.1|HLA-Cw-2 
P13746.1|HLA-A-11   P30685.1|HLA-B-35  P04222.2|HLA-Cw-3 
P18462.1|HLA-A-25     Q04826.1|HLA-B-40  P30504.1|HLA-Cw-4 
P30512.2|HLA-A-29   P30481.1|HLA-B-44  Q9TNN7.1|HLA-Cw-5 
P10314.2|HLA-A-32  P18465.1|HLA-B-57 
 
4.4 Multiple Sequence Alignment 
 
MSA is the first step to analyse the sequence, function, and structure of biomolecules. The used 
aligner in this project was MUSCLE (multiple sequence comparison by log-expectation) (Edgar, 
2004). MUSCLE is a progressive method for multiple sequence alignment. After generating the 
initial alignment, an optimal solution can be achieved by repeatedly modifying the suboptimal 
solution until no more improvement in the aligning score exists. The used parameters were as 
follows: the format for the generated multiple sequence alignment was Pearson/FASTA and the 
guide tree to output was set to zero. The resulting aligned FASTA file was imported to Clustal X 
(Larkin et al., 2007) to evaluate the redundancy and misfitting of the sequences. The MSA result 
was viewed with the GeneDoc tool (Nicholas & Nicholas, 1997) that can also be used for editing 
and annotating multiple sequence alignments.  
 
4.5 Docking: Building the peptide-MHC I complexes 
 
The crystal structures from PDB are not immediately ready for molecular modeling. The 
experimental structures need to be first prepared by removing metal ions, water molecules and 
cofactors, if any, and adding the hydrogen atoms. Moreover, multimeric structures may need to 
be reduced to a single unit and if the protein chains have missing residues, they should be 
assigned. For this purpose, the Protein Preparation Wizard of Maestro (Schrödinger Suite 2018-
4) was used. In the preprocessing step, the following modifications were carried out: assign bond 
orders, add hydrogens, create disulfide bonds, filling missing side chains using Prime. Water 
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molecules beyond 5 Å from any non-protein groups were also removed. Further, the highest 
average occupancy position for any alternative amino acid side chain rotamers was selected. In 
the final step, the structure was refined with restrained minimization to remove steric clashes 
and relax side chains, allowing the heavy atoms to move at most 0.30 Å from their initial positions. 
After the protein structure preparation, Chimera v. 1.13.1 (Pettersen et al., 2004) was used to 
manually mutate the amino acids in the co-crystallized peptides of the PDB structures types, 
altogether eleven MHC I structures from PDB, (see section 4.2) to the corresponding residues of 
the ZIKV peptides (see Tables 1A-C ). Sidechain rotamers were selected from the Dunbrak 
backbone-dependent rotamer library (Shapovalov & Dunbrack, 2011). Generally, a large number 
of steric clashes were found between the new peptide atoms and atoms of the interacting 
residues at the MHC I binding groove. To remove such clashes and refine the structures, the built 
MHC I-peptide complexes were submitted to the FlexPepDock tool (Londen et al., 2011; Raveh et 
al., 2010). The number of low-resolution and high-resolution structures were set to 200. Rosetta 
FlexPepDock aims at building models of protein-peptide complexes whilst trying to overcome the 
issue of conformational flexibility of the peptide. It also helps to evaluate peptide binding 
affinities and specificities based on the generated models. The protocol can produce high-
resolution peptide-protein models by refining a coarse starting complex to a relatively native 
model. The protocol optimizes the peptide backbone and rigid body orientation by applying 
iteratively a Monte-Carlo approach and subsequent energy minimization. The hydrogen bonding 
interactions and steric clashes within resulting complexes were analyzed by Chimera. Donor-
acceptor distance limit was set as < 3.3 Å. 
 
4.6 Molecular Dynamics Simulations 
 
All the refined docked complexes and, for comparison, the experimentally determined complexes 
were submitted to a molecular dynamics (MD) simulation for further refinement. MD simulations 
were first developed at the theoretical physics community during 1950s (Alder & Wainwright, 
1957). The first MD simulation was performed using a crude molecular mechanics potential and 
only lasted for 9.2 ps (Artymiuk et al., 1979). MD presents the detailed physical motions and 
interactions of atoms of a molecule in a simulated environment (e.g. in vacuum or in water at a 
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certain temperature) as a function of time (Patodia et al., 2014). The regularly saved atomic 
coordinates over a course of time form the MD dynamics trajectory (different conformations) of 
a molecule. Multiple factors are substantial while performing a MD simulation; e.g. solvent, 
temperature and ions. The conformational flexibility of a protein in surface and loops is 
considerably related to the surronding environment. MD is an insightful approach that connects 
the structure and dynamics of a molecule by providing the means to study the conformational 
energy of proteins.  
It can be said that the force field is the cornerstone of a MD simulation (Vitkup et al., 
2000). MD simulations can be divided into two main categories; namely, classical molecular 
mechanics and quantum mechanics-based MD simulations. Since quantum mechanics-based MD 
simulation requires a huge amount of computational resources, currently the classical molecular 
mechanics-based simulation is the most common MD simulation method (Höltje et al., 2003). In 
molecular mechanics, a function that defines the energy of a molecule and describes the 
evolution of bonded (bond lengths, bond angles and torsions) and non-bonded (van der Waals 
and electrostatic interactions) interaction energies between atoms in a molecule over the course 
of time is called a force field. It is comprised of equations and parameters that determine the 
desired geometry of a particular molecule. The parameters for the function can be obtained 
either experimentally or theoretically. There are different force fields for different molecules 
based on the various atomic interactions within a molecule. In this study, the AMBER force field 
(Cornell, 1995; Elber et al., 1995) was applied.  
There are several MD simulation packages such as NAMD (James & Phillips, 2005), 
Gromacs (Pronk et al., 2013) and Amber (Case et al., 2005). Amber16 (Assisted Model Building 
and Energy Refinement) simulation package was used in this study. The tleap module of AMBER 
(the basic tool to construct the force field files) was used to prepare the proteins and peptides 
(add hydrogens, build disulfide bonds) and the simulation systems employing the AMBER ff03 
force field (Case et al, 2005). Each peptide-protein complex was dissolved in an octahedral TIP3P 
water (Jorgensen et al, 1983) box using Na+ as neutralizing counter ions. The minimum distance 
of the solute to the edge of the simulation box was set to 10.0 Å and periodic boundary conditions 
and particle-mesh Ewald electrostatics (Essman et al, 1995) with a cut-off of 9 Å for non-bonded 
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interactions were applied. SHAKE algorithm (Ryckaert et al., 1997) was applied to constrain the 
bonds to hydrogen atoms when using the 2-fs time step. 
After preparing the simulation systems, the potential energy of the systems was 
minimized using the same stepwise protocol as described by Mirza et al. (2016). The purpose was 
not to find a global energy minimum but to find local minima on the potential energy surface and 
to obtain favorable bond lengths and bond angles minimizing the force pulling or pushing atoms 
together, removing the possible steric clashes and adjusting the distribution of solvent molecules 
(Dalke et al., 1997). 
Before the actual production simulations, all the systems were equilibrated. The aim of 
this step is to equilibrate the energy of the system, relax the structure and the solvent.  
Equilibration was performed in five steps, using a time step of 1 fs for the Langevin dynamics 
steps 1-4 and 2 fs for the last step of conventional dynamics. The protocol followed that of Mirza 
et al. (2016). Shortly: 
Step 1: Heating the system for 10 ps from 10 K to 300 K at constant volume using Langevin 
dynamics [gamma_ln (collision frequency) = 1.0 ps-1], with a fixed solute (restraint force constant 
5 kcal/molÅ2). 
Step 2: A new heating of the system for 20 ps from 10 K to 300 K using Langevin dynamics 
[gamma_ln = 1.0 ps-1], no positional restraints. 
Step 3: Equilibration of the system for 20 ps at constant temperature (300 K) and constant volume 
using Langevin dynamics [gamma_ln = 0.5 ps-1], no positional restraints. 
Step 4: Equilibration of the system for 50 ps at constant temperature (300 K) and constant 
pressure of 1.0 bar using Langevin dynamics [gamma_ln = 0.5 ps-1] to adjust the density of the 
system, no positional restraints. 
Step 5: Equilibration of the system for 400 ps at constant temperature (300 K) and constant 
pressure of 1.0 bar (coupling constant for temperature = 5.0 ps and for pressure = 2.0 ps), using 
conventional MD, no positional restraints. 
 The actual production simulation was run at constant temperature of 300 K and pressure 
of 1 bar and the length of the production run was 10 ns. The coupling constants for temperature 
and pressure were 5.0 and 2.0 ps, respectively. In this step, velocities and coordinates of system 
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are saved as trajectories to be analyzed.  
 
4.7 Analysis of the stability of the peptide-MHC I interactions 
 
The cpptraj module of AmberTools16 was used to analyze the trajectories from the MD 
simulations (Roe & Cheathman III, 2013). Root Mean Square Deviation (RMSD) calculation is the 
most common way to measure how stable a structure remains during the simulation. RMSD is 
the distance between the corresponding positions of two atoms in the two structures (e.g. the 
starting structure before MD simulation and the final structure after MD simulation). It is a global 
measurement and calculated with respect to one reference structure (Devadoss & Raj, 2014). We 
used the starting structure as the reference and compared its backbone atoms with the backbone 
atoms of all the saved structure conformations along the trajectory. We also calculated RMSD of 
Cα atoms between the initial docked peptide conformation and the minimized conformation after 
the MD simulations. Root Mean Square Fluctuations (RMSF) of atoms per residue were also 
calculated. The RMSF graphs show which residues fluctuate the most or least and provide thus 
information on for example which of the peptide residues are engaged in stable/tight interactions 
(anchor residues) with the receptor and which ones are free to move more. 
 Prime-MMGBSA (Molecular Mechanics Generalized Born Surface Area) module of 
Maestro was used to estimate the free energy of binding of the peptides both in the initial (crystal 
or docked) complexes as well as the final minimized complexes from the MD simulations 
(Schrödinger, 2016). Prime-MMGBSA binding energy for the final complexes was calculated using 
a rigid peptide-MHC I complex (Jacobson et al., 2002; Jacobson et al., 2004; Schrödinger 
Release 2018-1: Maestro/Prime, Schrödinger, LLC, New York, NY, 2018) 
Residues that bind to the MHC I can be identified by their high degree of burial (Höltje et 
al., 2003). For this purpose, the solvent accessible surface area (SASA) was calculated for the 
peptide residues with NACCESS v. 2.1.1 (Hubbard & Thornton, 1993) to evaluate their binding to 
the MHC I pockets or availability to interact with a TCR. The program uses the Lee & Richard’s 
(1971) method. The SASA value depends on the tightness, strength and the number of 
interactions of the peptide residues with the MHC I pocket and is a measure of a residue’s depth 
of binding to the pocket (Höltje et al., 2003). The measurement unit is square Ångströms (Å2) and 
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the result is given as a relative accessibility (%) value for all atoms of a particular residue. 
 Change in the size of the MHC I subpocket F was also measured before and after the MD 
simulation. It has been suggested that a tightly binding peptide closes the MHC I binding groove 
and a poorly binding peptide widens the groove (Fleischmann et al., 2015) and the size of the 
flexible F pocket can give some insight into the groove size (Abualrous et al., 2015). For this 
purpose the distances between Cα atom of residue 74 in α1 helix and residue 149 in α2 helix (d1) 




5. Results and Discussion 
 
In this chapter we will first analyze the results from the Multiple Sequence Alignment for different 
MHC I HLA types, namely HLA-A, HLA-B, and HLA-C to find the degree of conservation/variability 
particularly in the peptide-binding domain. Knowing about the variability in different alleles of 
MHC I HLA molecules will assist to explain the broad specificity of MHC I molecules to a wide 
range of antigens. 
Next, we will proceed to the analysis of the docked peptide-MHC I complexes compared 
to the experimentally determined peptide-MHC I (crystal) complexes before the MD simulation. 
This will give insight into the goodness of the docked poses. For example, are there big steric 
clashes between the peptide and the MHC I binding pocket? Do the predicted peptides have 
similar interactions with the MHC I binding groove compared to an experimentally verified 
peptide? Moreover, analyzing the complexes before and after the MD simulation helps us to 
evaluate the significance of MD in refining the peptide binding poses in the MHC I groove. 
Eventually, we will analyze the resulting trajectories from the MD simulations. In this section, we 
will discover how the different ZIKV peptide-MHC I complexes behave during the simulations with 
the aim to find the most stable complex, i.e. the peptide that has the best binding affinity to the 
MHC I binding groove. Such a peptide or peptides could be suitable candidates for the design of 
a vaccine against the ZIKV infection. Here, the analyzed complexes include both experimentally 
determined (crystal) and docked peptide-MHC I complexes. The crystal complexes act as a 
reference to compare the binding of the docked peptides with the experimentally verified binding 
of antigenic peptides (co-crystalized peptides).  
As mentioned before, we had eleven experimental peptide-MHC I structures from PDB 
plus two docked ZIKV peptide complexes for each experimental MHC I structure; altogether, we 
analyzed 33 complexes. We analyzed the predicted antigenic peptides derived from the ZIKV E 
protein in complex with the following MHC I HLA structures: HLA-A*0101 and HLA-A*0201 and 
the peptides from the ZIKV NS3 protein in complex with HLA-B*2705 and the peptides from ZIKV 
NS5 protein in complex with HLA-C*0801. The reason for using several different crystal structures 
of the HLA-A*0201 molecule was to identify the key residues interacting with different antigenic 
peptides. We wanted to investigate if there was any consensus binding pattern for all the binding 
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peptides or significant variation in binding interactions depending on the antigenic peptide 
bound. 
 
5.1 Multiple Sequence Alignment 
 
To investigate the degree of conservation among the MHC I HLA molecules, especially in the 
peptide-binding groove (active site), sequences were aligned with the MUSCLE algorithm. As it 
can be seen from the alignment (Figure 6.1), the gap-free areas are mostly belonging to the more 
rigid parts corresponding to the core areas of the protein while the gap-rich areas belong to the 
more flexible parts such as loop regions. In addition to the gaps, physicochemical characteristics 
of amino acids are another criterion when investigating MSAs. A change in the type of an amino 
acid in a sequence can, in turn, lead to a change in the protein structure and characteristics. 
Generally, the charged amino acids, namely lysine, arginine, glutamic acid and aspartic acid are 
common residues involved in ligand binding. 
HLA genes are extremely polymorphic. It means most HLA genes consist of a huge number 
of allelic variants. Among the MHC I molecules, HLA-B has the greatest number of allelic variants 
(Reche & Reinherz, 2003). Although variations in the sequence are distributed through the whole 
sequence of the MHC I molecules, these polymorphic sites are more notable in the α1α2 domain 
(residues 1 to 180) which form the peptide-binding cleft (Clements et al., 2005; Reche & Reinherz, 
2003).   It should also be noted that the number of variable amino acids is higher in the region 










Figure 6.1. Multiple Sequence Alignment of α1 and α2 domain (residues 1-180) from the HLA-A, HLA-B and HLA-C 
alleles. The twenty sequences were obtained from the UniProt database and aligned by the MUSCLE algorithm. Blue, 
red and green arrows demonstrate the polymorphic peptide contact sites for HLA-A, HLA-B and HLA-C molecules, 
respectively. The alignment was visualized with the GeneDoc tool. 
Black background shading with white text indicates that a single residue is conserved across the entire alignment. 
The second level of shading is a dark gray background with white text. It identifies the columns in the alignment 
where a single residue is conserved in all of the sequences and the third level of shading with black text and gray 
background color identifies the columns in the alignment where a single physicochemical property group is 
conserved in all of the sequences (Nicholas & Nicholas, 1997).  
 
Reche and Reinherz’ (2003) study reinforces this notion. They calculated sequence variability 
from relevant multiple sequence alignments of HLA types A, B and C and defined a variability 
metric (V) that was plotted for each site in the alignment. Their result showed that all peptide-
binding residues obtained V>1 (polymorphic site). They also showed a variability profile for each 
HLA molecule which is consistent with our alignment (Figure 6.1): residues 9, 62, 76, 114 and 156 
in the HLA-A, residues 45, 67, 97, 116, 156 and 163 in the HLA-B and residues 9, 116, 156 and 163 
in the HLA-C are the most variable sites in each MHC I HLA group. These profiles demonstrate the 
specificity of peptide-binding in different MHC I allels. When this variability profile is mapped 
onto the 3D structure of the MHC I molecules, some residues, such as 9 and 114 in HLA-A reside 
in the β-sheet that forms the floor of the peptide- binding groove, while residues 67 in HLA-B and 
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156 in HLA-C locate on the α-helices (Figure 6.2). It can be concluded that the greatest diversity 
is exhibited by the binding groove (α1α2 domain), in consistence with the observed 
polymorphism. In sum, each HLA molecule has its variability profile and this high level of allelic 





Figure 6.2. Sequence variability in the peptide-binding groove (α1α2 domain) of the MHC I HLA molecules. (A1-C1) 
The peptide-binding groove depicted using the ribbon style denoting the most variable residue sites in HLA-A, HLA-
B, HLA-C. The following PDB structures were used for rendering the conservation attributes: HLA-A: 5SWQ, HLA-B: 
2BST, HLA-C: 4NT6. Red color denotes the non-variable areas; blue denotes variable regions and white represents 
the intermediately variable regions. AL2CO was selected as Conservation style (Pei & Grishin, 2001). The images were 
created with Chimera v. 1.13.1.  
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5.2 Evaluation of the docking results in the light of the MD refinement 
 
5.2.1 Peptides from the ZIKV E protein 
 
Structural analysis of the co-crystalized CTELKLSDY peptide bound to the HLA-A*0101 molecule 
(PDB ID: 4NQV, resolution of 2.4 Å) indicated that residues at peptide positions P2 (Thr) and P9 
(Tyr) are the anchor residues while the residue at P3 (Glu) is buried in the D pocket forming a salt 
bridge with Arg156. Residues at P4 (Leu), P5 (Lys) and P8 (Asp) are exposed to the solvent (Table 
2A). However, the P8 backbone atom (O) interacts with Trp147. An extended peptide 
conformation stabilizes the HLA-A*0101 molecule and these interactions enhance the stability of 
the complex, leading to the peptide presentation to TCR and immunogenicity. Evaluation of the 
docking results of the predicted antigenic peptides TMNNKHWLV and GLDFSDLYY from ZIKV E 
protein complexed with HLA-A*0101 indicated that the two peptides retained some of their initial 
hydrogen bonds during the MD refinement. However, this was more remarkable for GLDFSDLYY 
(Table 2A). Tyr159 (atom OH) interacting with the peptide backbone (P1 oxygen) is the only 
residue retaining its interaction in both initially docked complexes and after MD simulation 
complexes. Glu63 (atoms OE1 and OE2), Asn77 (atom OD1) and Lys146 (atom NZ) seem to be the 
most crucial residues in this HLA molecule since they participate in hydrogen bond interactions in 
the experimental complex both before and after the MD simulation. Among the peptide residues, 
residue 9 (Tyr) from GLDFSDLYY has the largest number of H-bond interactions in the pocket F 
(Table 2A). 
 The two docked complexes exhibit an increased number of H-bond interactions in the 
peptide-binding groove after the MD simulation (Table 2A). No steric clashes were found in the 
initial docked complexes or after the MD simulation. Besides, the GLDFSDLYY-HLA complex has a 














































aDocked ZIKV E   peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera v. 1.13.1  (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance 
between the H-bond donor and acceptor after molecular dynamics (MD) simulation. Stars denote the existence of 









Db init Dc MD Db init Dc MD Db init Dc MD 
P1(N) GLU 63 OE1   * 3.448       * 2.693 
GLU 63 OE2   * 2.751     
 
    
TYR 159 OH * 2.671 * 2.637         
P1(O) TYR 159 OH 
 
    * 2.757 * 3.142 * 2.743 * 2.664 
P1(OG1) GLU 63 OE1       * 2.588     




* 2.742   * 3.264   
 
  
GLU 63 OE2 
 
* 2.755   * 3.223 
 
* 2.868 * 3.327   
P2(O) ARG 163 NH2 * 2.609   * 2.861   * 2.835   
ARG 163 NH1     * 3.411   * 3.297   
P2(OG1) GLU 63 OE2   * 2.597       * 2.869 
P3(OD2) ARG 156 NH1   * 2.939     * 2.895 * 2.865 
P3(OE1) ARG 156 NH1 * 2.872           
P6(OD1) ARG 114 NH2         * 2.918 * 2.869 
P7(O) ASN 77 ND2 * 3.268 * 2.840 * 3.336   * 3.248 * 3.411 
ARG 114 NH1   * 2.961         
P7(N) THR 73 OG1       * 3.060     
P8(O) TRP 147 NE1 
 
* 2.782 * 2.812 * 3.174   * 2.881 * 2.902 
P9(N) ASN 77 OD1 * 2.946   * 3.060 * 3.301 * 3.127 * 2.980 
P9(O) TYR 84 OH 
 
  * 2.868   * 2.683   
 
  
THR 143 OG 
 




LYS 146 NZ 
 
  * 3.043   * 3.170     
P9(OH) ASP 116 OD2 * 2.460 * 2.693     * 2.712 * 2.672 
P9(OXT) LYS 146 NZ 
 
  * 2.801   * 2.806   * 2.859 
THR 80 OG1       
 
    * 2.604 
Total no. of interactions 8  14  7  9  10  11  
 
Side chain interactions 2  3 
 
 -  2  3  4  
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The co-crystallized GLMWLSYFV peptide (from SARS coronavirus membrane protein) is deeply 
buried via residues at P2 (Leu) and P9 (Val) in the B and F pockets of the HLA-A*0201 (PDB ID: 
3I6G) peptide-binding groove, respectively. The other two anchor positions, known as secondary 
anchor residues are located at P3 (Met) and P6 (Ser). Met3 resides in the subpocket D and Ser6 
is buried in the subpocket C (Liu et al, 2010). These interactions enhance the stability of the 
complex. The peptide FSDLYYLTM from ZIKV E protein docked to the 3I6G structure forms 
hydrogen bonds via P1 and P2 backbone atoms (O and N) in the N-terminus of the peptide in the 
same way as the co-crystalized peptide does, whereas Met1 of MAEVRSYCY is not involved in 
binding to the HLA-A*0201 binding groove in this particular HLA-A*0201 structure (Appendix 2E; 
PDB ID: 3I6G). Moreover, the C-terminal segment (positions P8 and P9) of both MAEVRSYCY and 
FSDLYYLTM are involved in binding to the MHC I cleft. The difference in the binding pattern for 
the two predicted peptides is observed for the central residues (P4 to P7). Residues at P4 and P6 
of MAEVRSYCY are involved in the hydrogen bonding network with the binding groove of the HLA 
molecule similarly to the co-crystalized peptide while those residue positions in FSDLYYLTM  might 
rather interact with the TCR. These differences contribute to differential T-cell recognition which  
leads to diverse immunogenicity. Trp147, Tyr159, and Asp77 are the most crucial residues in this 
MHC I HLA molecule to interact with the co-crystallised peptide as well as the docked peptides. 
Table 3 presents the FlexPepDock hydrogen bonding energy for the two docked 
complexes, that of FSDLYYLTM being slightly better (-23.087 kg/mol). No steric clashes were 
observed in the complexes after manual docking and FlexPepDock refinement nor after the MD 
simulation for either of the docked peptides. 
The most important residue for interacting with the peptides in the HLA-A*0201 structure 
PDB ID: 3TO2 is Trp147. It interacts with the docked peptides (MAEVRSYCY and FSDLYYLTM) as 
well as the co-crystallized peptide (LACFVLAAV from SARS coronavirus membrane glycoprotein) 
(Appendix 2F). Peptide positions P1, P2, P6, P8 and P9 are responsible for forming hydrogen bond 
interactions in the crystal complex and the docked complex with MAEVRSYCY , whereas P6 does 
not participate in H-bond interactions in the complex with FSDLYYLTM before MD. On the other 
hand, P3 (Glu) of MAEVRSYCY interacts with the binding groove only via the backbone oxygen 
whereas no interaction was formed between P3 and HLA crystal structure binding groove. H-
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bonding energies and the observed initial clashes between the docked peptides and the MHC I 
molecules are presented in Table 3. 
Post-docking analysis of the ZIKV E peptides docked at the HLA-A*0201 structure PDB ID: 
5SWQ revealed that the FSDLYYLTM peptide retained most of the initial hydrogen bonds within 
the binding cleft, whereas MAEVRSYCY could keep only two hydrogen bonds out of seven initial 
H-bonding interactions (Appendix 2H). Significant hydrogen bonds were formed between Cys8 
and Thr9 from both ZIKV E peptides and Trp147, Asp77 from the HLA protein. Hydrogen bonding 
energy values resulting from FlexPepDock were -23.288 kcal/mol and -24.398 kcal/mol for 
MAEVRSYCY and FSDLYYLTM, respectively (Table 3). Both peptides showed some initial clashes 
with the MHC I peptide-binding groove before the MD refinement but the clashes were removed 
after the MD simulation (Table 3). 
In addition, the post-docking results of MAEVRSYCY and  FSDLYYLTM in complex with  the 
other crystal structures of HLA-A*0201 (PDB IDs: 1OGA, 2GIT, 2GTZ, 2GTW and 4K7F) are 
presented in Table 3 and Appendices 2A-D and 2G, respectively. Overall, the post-docking analysis 
of the HLA-A*0201 structures in complex with the different predicted antigenic peptides revealed 
that all the analyzed HLA-A*0201 complexes share some identical amino acid residues that are 
involved in binding with the peptides. For instance, Glu63, Tyr159, Trp147 and Asp77 interacted 
with the bound peptide almost in all the HLA-A*0201 crystal structures. In sum, the binding 
interactions depend on the peptides but interactions with certain groove residues are especially 
favorable for the peptide binding.  
As it was mentioned earlier, choosing eight different crystal structures for the MHC I HLA-
A*0201 type was used for investigating the crucial interacting residues of the HLA-A*0201 
molecule to find a possible consensus binding pattern for the peptides. Looking at the interacting 
residues in the binding-groove of the HLA-A*0201 crystal complexes revealed that despite the 
identical interacting residues from HLA-A*0201 (Glu63, Tyr159, Trp147 and Asp77) with P2 and 
P9 (the main anchor residues of the peptides), there are also some variable interacting residues 
binding with the partial anchor residues (at P1, P3, P6 and P8) or the central region residues (at 
P4-P7). These impact the orientation adopted by the main anchor residues, which then affects 
the adopted pose of the peptide inside the MHC I binding-groove, which in turn affects the 
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stability and, finally, the immunogenicity of the presented peptide. The crystal complex PDB ID: 
5SWQ is a good example on this. The aromatic residue Phe at P7 of the CVNGSCFTV peptide (an 
NA231 influenza epitope) is buried inside the groove and interacts with Trp147 of the HLA 
molecule and is not solvent-exposed (Appendix 2H). This affects the conformation of Cys6 in such 
a way that the general SASA of the peptide is reduced (Grant et al., 2016). 
In conclusion, structural analysis of the experimentally determined HLA-A*0201 
complexes demonstrated that the peptides LLFGKPVYV (PDB ID: 2GIT), ALGIGILTV (PDB ID: 2GTZ) 
and GLMWLSYFV (PDB ID: 3I6G) form more stable complexes than the other peptides in the HLA-
A*0201 crystal complexes. This is due to the different interacting residues engaged in such 
complexes beside the identical interacting residues. For example, LLFGKPVYV engaged Tyr171 and 
Tyr 84 with its residues at P1 (Leu) and P9 (Val), respectively. ALGIGILTV engaged Tyr 59 with its 
P1 (Ala) and Arg97 was interacting with P6 (Ser) of GLMWLSYFV. Interestingly, Tyr171 was also 
involved in interacting with P1 of the two docked peptides (MAEVRSYCY and  FSDLYYLTM) and 
Tyr84 was involved in interacting with FSDLYYLTM. However, neither Tyr59 nor Arg97 formed any 
interactions with the docked peptides. 
 
5.2.2 Peptides from the ZIKV NS3 protein 
 
Previous studies have revealed that the arginine at P2 in the co-crystalized peptide SRYWAIRTR 
(derived from Influenza A virus H1N1) is an anchor for the peptide to accommodate in the MHC I 
HLA-B*2705 (PDB ID: 2BST) pocket B. It was suggested that the acidic Asp116 from pocket F plays 
a crucial role in the intaraction with the basic arginine at P9 (Jardetzky,  1991; Madden et al., 
1991; Madden et al., 1992). The P9 arginine contacts both Asp77 and Aps116 in the base of the 
F pocket through a salt bridge. There is also a salt bridge between Glu63, Glu45 and the arginine 
at P2. The central region of the peptide (P4-P7) is located out of the binding groove.  
Evaluation of the docking results for the ZIKV NS3 peptides (DIGAVALDY, HSEVQLLAV) 
docked at the HLA-B*2705 structure demonstrated a more strong hydrogen bonding energy for 
DIGAVALDY (-21.251 kcal/mol) than HSEVQLLAV (-16.589 kcal/mol) (Table 3). Six hydrogen bonds 
formed between the DIGAVALDY peptide and the HLA-B*2705 molecule (Table 2B). The strongest 
hydrogen bond formed between the backbone oxygen of Asp8 with the side chain nitrogen (NE1) 
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of Trp147 while the weakest H-bond formed between Asp1 (N) and Tyr59 (OH) which is part of 
the subpocket A. Pocket B demonstrates a quite strong H-bond interaction between Ile2 (N) and 
Glu63 (OE1). Tyr9 could form two H-bonds in pocket F with Asp77 (OD1) and Lys146 (NZ).  
On the other hand, another predicted epitope HSEVQLLAV from the ZIKV NS3 protein 
formed eight H-bonds with HLA-B*2705 (Table 2B). Five H-bonds were formed between His1 from 
the peptide and Glu63, Tyr59, Arg62 and Tyr159 from the subpocket A in the MHC I molecule. 
One H-bond interaction is between Glu63 from the HLA-B*2705 molecule and Ser2 from the 
peptide and the other two H-bonds are between Trp147 and Asp77 from the MHC I, and Ala8 and 
Val9 from the peptide, respectively. Peptide residues 4 to7 did not form any interaction with the 
MHC I molecule, the rule that is followed by the co-crystalized peptide as well. It should be 
mentioned that there existed an initial steric clash between Tyr9 (HH atom) from DIGAVALDY and 
Arg96 (HE atom) from HLA-B*2705, whereas no clash was found in the HSEVQLLAV-HLA-B*2705 
complex. No steric clashes were observed in the complexes after the MD simulation.
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Table 2B. Hydrogen bonding interactions in HLA-A*2705 (PDB ID: 2BST) complexes. 
 
aDocked ZIKV NS3 peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera v. 1.13.1 (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance 
between the H-bond donor and acceptor after molecular dynamics (MD) simulation. Stars denote the existence of 









Db init Dc MD Db init Dc MD Db init Dc MD 
P1(N) GLU 63 OE1       * 2.727   * 2.706 
TYR 7 OH 
 
    
 
    
 
* 2.852   
GLU 63 OE2 
 
  * 3.184       * 3.321 
GLU 45 OE2 
 
          * 2.781 
TYR 59 OH     * 3.509   * 3.042   
P1(ND1) ARG 62 NE         * 3.154   
ARG 62 NH2         * 3.080   
P1(O) TYR 159 OH 
 
* 2.560 * 2.743 * 2.855   * 2.789   
P2(N) GLU 63  OE1 
 
  * 2.864 * 2.984       
GLU 63 OE2 * 2.928       * 2.888   
P2(NE) GLU 45 OE2 * 2.609 * 3.169         
P2(NH1) THR 24 OG1 * 2.836 * 2.865         
P2(NH2) THR 24 OG1 * 2.957           
GLU 45 OE2 * 2.715 * 2.748         
P2(O) LYS 65 NZ * 3.187           
TYR 159 OH           * 2.766 
P3(OE1) LYS 70 NZ           * 3.482 
P3(OE2) LYS 70 NZ           * 2.760 
P5(OE1) GLN 155 NE2           * 2.800 
P6(O) LYS 70 NZ   * 2.747         
P8(O) TRP 147 NE1 * 2.903       * 2.783   
P8(OD1) LYS 146 NZ       * 2.878     
P9(N) ASP 77 OD1 * 2.790 * 2.967 * 2.864   * 2.892 * 3.462 
 ASP 116 OD1   * 3.462         
ASP 116 OD2   * 2.723         
P9(O) LYS 146 NZ * 2.487   * 2.889       
TRP 147 NE1     * 2.762       
 
P9(NE) ASP 116 OD1 * 2.652 * 2.862         
ASP 116 OD2   * 3.135         
P9(OXT) LYS 146 NZ   * 2.862         
TYR 84 OH * 2.537           
Total no of interactions 12  13  6  2  8  8  
 
Side chain interactions 4  5  _  1  2  4  
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5.2.3 Peptides from the ZIKV NS5 protein 
 
The co-crystallized GILGFVFTL peptide (derived from Influenza A virus) is held in the B and F 
pockets of the MHC I HLA-C*0801 peptide-binding groove via the anchor residues at P2 (Ile) and 
P9 (Leu), respectively (PDB ID: 4NT6). This particular peptide shows very similar interactions in 
complex with HLA-A*0201 (PDB ID:1OGA). Ser77, Asn80, Lys146 and Phe116 in pocket F of HLA-
C*0801 interact with the antigenic peptide while in HLA-A*0201 the corresponding residues are 
Asp77, Thr80, Lys146 and Tyr116. GILGFVFTL is accommodated in the F pocket through hydrogen 
bonding with residues 77, 80, 146 and hydrophobic interaction with residue 116 in both HLA 
structures. Similarly, the B pocket also engages the antigenic peptide in hydrogen bonding via 
Glu63 and Lys66 and hydrophobic interaction via Met45 in HLA-C*0801 and Tyr7 in HLA-A*0201. 
It should be mentioned that apart from Tyr7 and Tyr9, residues of the binding-groove floor do 
not form any notable bonds with the peptides (Choo et al., 2014). 
Docking results for the ZIKV NS5 peptides (MTTEDMLVV, FTNLVVQLI) docked into the HLA-
C*0801 molecule suggest that Ser77, Asn80 and Lys146 are the significant residues from the MHC 
I molecule that hold the ZIKV NS5 peptides inside the F pocket (Table 2C). The hydrogen bond 
energy values resulting from FlexPepDock are -24.163 kcal/mol and -24.269 kcal/mol for 
MTTEDMLVV and FTNLVVQLI peptides, respectively. One steric clash was found between Thr2 
(HG1 atom) of the peptide and Tyr9 (HH atom) of the MHC I molecule (Table 3). The greater 
number of interactions observed in the F pocket compared to the B pocket suggests that the F 
pocket plays a more significant role in providing stability to the complex. 
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aDocked ZIKV NS5 peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera v. 1.13.1 (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance 
between the H-bond donor and acceptor after molecular dynamics (MD) simulation. Stars denote the existence of 








Db init Dc MD Db init Dc MD Db init Dc MD 
P1(N) GLU 63 OE1   * 2.776       * 3.088 
GLU 63 OE2   * 2.852     * 3.278 * 2.754 
TYR  9 OH * 2.802   * 2.431       
TYR 7 OH * 2.608       * 2.822   
TYR 171 OH     * 2.851       
TYR 59 OH   * 2.851         
P1(O) TYR 159 OH * 2.658 * 2.713 * 3.009   * 3.294   
GLU 63  OE1       * 3.129 * 2.882   
GLU 63 OE2       * 2.722     
P2(O) LYS 66 NZ * 2.831           
P2(N) GLU 63 OE2 * 2.853 * 2.855         
P2(OG1) GLU 63 O           * 2.896 
TYR 9 OH     * 2.431       
GLU 63 OE2       * 2.608     
P3(O) GLN 70 NE2     * 3.380 * 2.946     
P3(N) TYR 99 OH * 3.091           
P3(OG1) TYR 159 OH       * 3.146     
P4(N) GLN 70 OE1           * 2.890 
P5(O) GLN 70 NE2           * 2.930 
P5(OD1) GLN 155 NE2       * 3.312     
P5(OD2) GLN 155 NE2       * 2.863     
GLN 155 NE2       * 2.931     
P7(OE1) ARG 97 NH1           * 2.995 
ARG 97 NH2           * 2.810 
GLN 70 NE2           * 3.409 
P8(O) TRP147 NE1 * 2.966 * 2.918 * 2.965 * 2.931 * 2.812 * 2.868 
LYS 146 NZ * 3.091           
P8(OG1) LYS 146 NZ * 2.613 * 2.939         
P9(N) SER 77 OG * 3.006 * 3.037 * 3.047   * 3.114   
P9(O) ASN 80 ND2 * 2.937 * 2.958 * 2.943 * 3.127 * 2.820   
LYS 146  NZ * 2.863   * 2.845     * 3.116 
P9(OXT) LYS146 NZ * 2.963     * 2.804   * 3.008 
THR 143  OG1   * 2.662       * 2.654 
TOTAL no of interactions 13  10  9  11  7  12  
Side chain interactions 1  1  1  5  -  4  
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Table 3. FlexPepDock energy for the peptide-MHC I complexes after the refinement of the built 
complexes and the measured steric clashes 
 Steric Clasha FlexPepDock Steric Clasha FlexPepDock 




















ZIKV E protein peptide: MAEVRSYCY ZIKV E protein peptide:  FSDLYYLTM 
 
GLU 5 H   TYR 99 HH 0.994 1.006 -23.01 -531.123 ASP 3 H  TYR 99 HH 0.807 1.193 -24.090 -536.234 
GLU 5 N   TYR 99 HH 0.659 1.966 - - - 
TYR 9 HH  TYR 116 HH 0.637 1.363 - - - 




- - - -20.623 -538.840 - - - -21.697 -541.334 




- - - -25.101 -524.232 - - - -27.022 -539.109 
 




More than 20 clashes   -21.090
  





GLU 5 H  TYR 99 HH 0.878 1.122 -21.535 -474.067 PHE 1 H2  TYR 7 HH 0.847 1.153 -23.087 -476.302 
GLU 5 N  TYR 99 HH 0.667   1.122 PHE 1 N   TYR 7 HH 0.806 1.819 




TYR 9 HH  ARG 97 HH 0.991 1.009 -23.682 -485.236
  
- - - -21.756 -489.814 
TYR 9 HH ARG 97 NH2 0.680 1.945 - - - 
MET 1 H1  TYR 7 HH 0.641 1.359 - - - 




TYR 9 HH  ARG 96 HE 0.747 1.253 -19.069 -524.893 PHE 1 N  TYR 6 HH 0.777 1.848 -20.432 -527.281 





TYR 9 HH  ARG 97 HH 0.841 1.253 -23.288 -487.568 PHE 1 H1  TYR 7 HH 0.714 1.286 -24.398 -490.135 
GLU 3 H   TYR 99 HH 0.673 1.327 - - - 
MET 1 H1  TYR 7 HH 0.626 1.374 - - - 
TYR 9 HH  ARG 97 NH2 0.617 2.008 - - - 
No steric clashes were  found after MD simulation 
   
2BST 
(HLA-B*2705) 
ZIKV NS3 protein peptide: DIGAVALDY 
 
ZIKV NS3 protein peptide: HSEVQLLAV 
 
TYR 9 HH  ARG 96 HE 0.747 1.253 -21.251 -515.097 - - - -16.589 -521.751 




ZIKV NS5 protein peptide : MTTEDMLVV ZIKV NS5 protein peptide: FTNLVVQLI 
THR 2 HG1  TYR 9 HH 0.704 1.296 -24.163 -536.303 - - - -24.269 -535.095 
 




ZIKV E protein peptide: TMNNKHWLV ZIKV E protein peptide: GLDFSDLYY 
- - - -26.705 536.634 - - - -27.953 541.860 
No steric clashes were  found after MD simulation 
aSteric clashes were measured with Chimera; bAllowed overlap is 0.6 Å; H-bond overlap reduction is 0.4 Å; cH-bond 
energy is for the side chain-side chain interaction (kcal/mol); dTotal score is Rosetta energy.  
34 
 
5.3 Evaluation of the molecular dynamics simulation trajectories 
 
MD simulations of the peptide-MHC I complexes were performed in explicit water at 300 K for a 
period of 10 ns to investigate the stability of the docked peptide-MHC I protein complexes and 
comparing the result with the behavior of experimentally verified antigenic peptides (reference 
peptides). In general, the potential energy of all simulation systems remained stable during MD 
simulation. Several parameters were measured before, during and after the MD simulation to 
analyze the quality and strength of ZIKV peptide binding to the studied MHC I proteins. These 
parameters included hydrogen bonding network (see Tables 2A-C, Appendices 2A-H), RMSD of 
the MHC I peptide-binding domain as well as the peptide molecule with respect to the starting 
structure, atomic fluctuations and solvent accessibility of the peptide residues, peptide 
interaction energies (free energy of binding) and the size of the F pocket both in the initial 
complexes as well as the final structures from the  MD simulations. Here the aim was to find the 
most stable peptide-MHC I complex in order to predict the ZIKV peptide or peptides with the 
highest binding affinity to the MHC I binding groove. Such high-affinity peptides could be suitable 
candidates for design of a vaccine against the ZIKV infection. 
 
5.3.1 HLA-A*0101 in complex with ZIKV E protein peptides 
 
In this section, we will review the analysis of the following MHC I complexes with the predicted 
antigenic peptides from the ZIKV E protein and the experimental peptide from the respective 
MHC I crystal structure: 
 
HLA-A*0101 (PDB ID: 4NQV) in complex with ZIKV peptides TMNNKHWLV and GLDFSDLYY and 
the co-crystalized peptide CTELKLSDY. 
 
Inspection of the hydrogen bonding network of the predicted ZIKV E epitopes TMNNKHWLV and 
GLDFSDLYY complexed with HLA-A*0101 demonstrated that peptide GLDFSDLYY forms a larger 
number of H-bond interactions in the binding groove of the MHC I molecule than peptide 
TMNNKHWLV. However, the number of H-bond interactions with TMNNKHWLV increased during 
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the simulation (Table 2A). Free energy of binding, calculated by the Prime-MMGBSA approach, 
decreased (improved) for the GLDFSDLYY-HLA-A*0101 complex as well as the crystal complex 
CTELKLSDY-HLA-A*0101 after the MD simulation compared to the initial values while this value 
increased (worsened) for the TMNNKHWLV- HLA-A*0101 complex. Also, the F pocket enlarged in 
both docked peptide-MHC I complexes (Table 4, Appendix 3: Figure 11.1). 
RMSD of the peptide-binding groove and the bound peptides was used as another 
criterion to inspect the stability of the peptide-MHC I complexes. RMSD of the backbone atoms 
of the HLA-A*0101 binding groove was about 1.6-1.7 Å in both docked peptide-MHC I complexes 
(Figure 7.1). RMSD of the backbone atoms of the GLDFSDLYY peptide bound to HLA-A*0101 was 
about 1.2 Å, whereas peptide TMNNKHWLV had a higher value of about 2 Å (Figure 8.1).  
 
 
Figure 7.1. RMSD of the backbone atoms of the MHC I binding groove (residues 1-180 in PDB ID: 4NQV) during the 
10-ns MD simulation of the ZIKV E peptide–HLA-A*0101 complexes (green and red lines) and the reference 
complex (black line). 
 
            Atomic fluctuations are a significant indicator of the strength of a ligand’s binding that 
depends on hydrophobic and electrostatic interactions. High atomic fluctuations indicate loose 
binding and vice versa (Höltje et al., 2003). Therefore, in this study atomic fluctuations were 
computed for each docked complex to be compared with the fluctuations of the experimental 
complexes. While TMNNKHWLV demonstrates less atomic fluctuations inside the binding groove 
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in the N-terminal segment, GLDFSDLYY shows less fluctuation in its C-terminus (Figure 9.1).  
 
Figure 8.1. RMSD of the backbone atoms of the ZIKV E peptides (green and red lines) and the reference peptide 
(black line) bound to HLA-A*0101 (PDB ID: 4NQV) during the 10-ns MD simulation. 
 
 
Figure 9.1. Per-residue RMS fluctuations of the ZIKV E protein peptides (green and red lines) and the reference 






SASA has also been known as an excellent measurement to evaluate the affinity of a peptide and 
it may be used as the decisive criteria to select the good binders from various peptides (Höltje et 
al., 2003). As it can be seen from the plot in Figure 10.1, GLDFSDLYY mimics the behavior of the 
co-crystallized peptide especially at positions P2 and P9 (anchor residues). 
 
 
Figure 10.1. Per-residue relative solvent accessibility of the ZIKV E protein peptides (green and red lines) and the 
reference peptide (black line) in the binding groove of MHC I HLA-A*0101 (PDB ID: 4NQV) after the MD 
simulations. 
 
Based on the above analysis, it can be concluded that GLDFSDLYY seems to form a more 
stable complex with the MHC I HLA-A*0101 than TMNNKHWLV. This suggests that it would have 
a better binding affinity to the MCH I molecule, thus being able to stimulate a strong immune 
response. 
 
5.3.2 HLA-A*0201 in complex with ZIKV E protein peptides 
 
In this section, we will review the analysis of the following MHC I complexes with the predicted 
antigenic peptides from the ZIKV E protein and the experimental peptides from the respective 




HLA-A*0201 (PDB IDs: 1OGA, 2GIT, 2GTW, 2GTZ, 3I6G, 3TO2, 4K7F, 5SWQ) in complex with the 
ZIKV peptides MAEVRSYCY and FSDLYYLTM as well as the co-crystalized peptides GILGFVFTL, 
LLFGKPVYV, LAGIGILTV, ALGIGILTV, GLMWLSYFV, LACFVLAAV, VCWGELMNL, CVNGSCFTV, 
respectively. 
 
PDB ID: 1OGA. MD analysis of the HLA-A*0201 molecule (PDB ID: 1OGA) in complex with the 
ZIKV E peptides MAEVRSYCY and FSDLYYLTM demonstrated that RMSD of the backbone atoms of 
the binding groove (residues 1-180) was about 1 Å in both the MAEVRSYCY-MHC I complex and 
the crystal complex (GILGFVFTL-MHC I) (Figure 7.2A). However, RMSD of the peptide-binding 
groove in the FSDLYYLTM-MHC I complex was somewhat larger (about 1.5 Å). On the other hand, 
in this crystal structure the co-crystalized peptide GILGFVFTL and the docked peptide FSDLYYLTM 
were more stable with a RMSD value of about 1.5 Å compared to the docked peptide MAEVRSYCY 
with a RMSD of about 2 Å (Figure 8.2A). The F pocket size was also enlarged in all the peptide-
HLA-A*0201 complexes, including the crystal complex (Table 4 and Appendix 3, Figure 11.2). The 
Prime-MMGBSA energy was lower (i.e. better) for the FSDLYYLTM-HLA-A*0201 as well as the 
crystal complex GILGFVFTL- HLA-A*0201 after the MD simulation compared to the initial values 
while this value rose (worsened) from -91.53 to -68.74 kcal/mol for the docked peptide 
MAEVRSYCY (Table 4). Besides, the RMS fluctuations of residues 2 and 9 of the both docked 
peptides in the binding groove were about 1 Å, which is comparable with the corresponding 
fluctuations of the co-crystalized peptide GILGFVFTL (about 0.7 Å) (Figure 9.2A). Moreover, the 
relative solvent accessibility (RSA) of residues 2 (P2) and 9 (P9) was about 20 percent for the two 
docked peptides showing that the residues in N-terminus (P2) and C-terminus (P9)  are deeply 
buried in the binding groove (B and F subpockets) of the  HLA molecule. The same trend was also 
observed for the co-crystalized reference peptide (Figure 10.2A). Inspecting the atomic clashes in 
the modeled complexes showed that three clashes existed between the atoms of peptide 
MAEVRSYCY and the MHC I binding groove, whereas no clash was found between the atoms of 
peptide FSDLYYLTM and the MHC I binding groove (Table 3). It is probable that the existence of 
such clashes affects the flexibility of MAEVRSYCY peptide inside the MHC cleft I, which then 
resulted in the low value of RMSD in the binding groove. Moreover, the evaluation of hydrogen 
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bonds before and after MD simulation revealed that MAEVRSYCY has retained three of the initial 
H-bonds in the binding groove after the MD simulation within 2.7 Å to 3.3 Å. One persistent 
interaction was between Arg97 and the glutamic acid at P3 of the peptide while methionine at 
P1 lost some of its initial H-bonds (Appedix 2A). No hydrogen bonds were formed at P2 (anchor 
residue) but Tyr9 at P9 formed two H-bonds via its backbone with Asp77 (OD2) and Lys146 (NZ). 
Peptide FSDLYYLTM exhibited more H-bonds inside the MHC I groove than MAEVRSYCY after the 
MD simulation. Additionally, as the binding of the peptide in the MHC I binding groove depends 
on the characteristics of the groove residues (Höltje et al., 2003), the larger number of aromatic 
residues in the FSDLYYLTM peptide than in MAEVRSYCY could improve the interaction between 
the peptide and the binding groove. 
 
PDB ID: 2GIT. Assessing the MD simulation of the HLA-A*0201 (PDB ID: 2GIT) complexed with the 
ZIKV E peptides MAEVRSYCY and FSDLYYLTM showed that RMSD of the backbone atoms of the 
binding groove was about the same for the two docked complexes: near 1.2 Å (Figure 7.2B). RMSD 
of the crystal complex (LLFGKPVYV-HLA-A*0201) was slightly higher (over 1.5 Å) for the MHC I 
peptide-binding domain. However, among all the three peptides the co-crystalized peptide 
LLFGKPVYV was the most stable in the binding groove with the RMSD value of only 0.5 Å. The 
second most stable peptide was the docked peptide FSDLYYLTM with the RMSD value of 1 Å. The 
docked peptide MAEVRSYCY had the highest RMSD value (about 2 Å), meaning that this peptide 
had the least stable pose in the binding groove of the studied MHC I structure (Figure 8.2B). 
Prime-MMGBSA free energies of binding were lower (better) than initially for all the complexes 
after the MD simulations (Table 4). The F pocket that binds the C-terminal area of the 
nonapeptides enlarged in size during the MD simulations in all the complexes (Table 4 and 
Appendix 3, Figure 11.3). Moreover, RMSF of the residue 2 (P2) and 9 (P9) of the docked peptide 
FSDLYYLTM in the binding groove is also comparable with the co-crystalized peptide (LLFGKPVYV), 
about 0.7 Å, which is significantly less than that of peptide MAEVRSYCY (about 1.7 Å) (Figure 
9.2B). This suggests that peptide FSDLYYLTM is able to bind more tightly to the binding groove of 
also this HLA-A*0201 structure. In addition, RSA of both the anchor residues (P2 and P9) in all 





PDB ID: 2GTW. MD analysis of the HLA-A*0201 (PDB ID: 2GTW) in complex with the ZIKV E 
peptides MAEVRSYCY and FSDLYYLTM showed again (see the 2GIT structure above) that RMSD of 
the backbone atoms of the binding groove in both the docked peptides adopted a smaller value 
of about 1.2-1.5 Å than the crystal complex (LAGIGILTV-HLA-A*0201) that adopted a value of 
about 1.7 Å (Figure 7.2C). Moreover, the co-crystalized peptide LAGIGILTV and the docked peptide 
FSDLYYLTM had a higher RMSD value of about 1 Å compared to the docked peptide MAEVRSYCY 
with a RMSD of about 0.5 Å (Figure 8.2C). Although RMSD for the backbone atoms of MAEVRSYCY 
is the smallest in this MHC I structure among all the HLA-A*0201 complexes (Figure 8.2), there 
was a huge increase (worsening) in Prime-MMGBSA energy of this complex (Table 4). It can be 
assumed that a large number of clashes between the peptide side chain atoms and the MHC I 
binding groove atoms prevented the peptide from moving freely in the binding cleft to obtain 
stability (Table 3). Another reason could be attributed to the short time of the MD simulation in 
which the complex could not reach the desired stability. From the docking evaluation, it was 
observed that the FSDLYYLTM-HLA-A*0201 complex retained more H-bonds than the 
MAEVRSYCY-HLA-A*0201 (Appendix 2C). On the other hand, the Prime-MMGBSA free energy of 
binding for the co-crystalized peptide LAGIGILTV and FSDLYYLTM was improved during the MD 
simulation (Table 4). The F pocket was also enlarged in the two docked peptide-MHC I complexes 
and the crystal complex (Table 4 and Appendix 3, Figure 11.4). Besides, the atomic fluctuation of 
residues 2 (P2) and 9 (P9) of MAEVRSYCY in the binding groove is higher than that of FSDLYYLTM 
and the co-crystalized peptide (Figure 9.2C). Further, the relative accessibility of the peptide 
residues 2 and 9 to the solvent was below 10 percent for the co-crystalized and FSDLYYLTM 
peptides. Thus, these residues in N-terminus (P2) and C-terminus (P9) are deeply buried in the B 
and F subpockets of the HLA molecule, respectively, which suggests stable binding to the MHC I 
molecule (Figure 10.2C). 
 
PDB ID: 2GTZ. MD analysis of the HLA-A*0201 (PDB ID: 2GTZ) complexed with the ZIKV E peptides 
MAEVRSYCY and FSDLYYLTM revealed that RMSD of the backbone atoms of the binding groove is 
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about the same for the two docked complexes (near 1.7 Å) (Figure 7.2D). However, RMSD for the 
MHC I peptide-binding domain of the crystal complex (ALGIGILTV-HLA-A*0201) was lower (below 
1.5 Å). In this structure, the co-crystalized peptide ALGIGILTV and the docked peptide MAEVRSYCY 
were more stable with a RMSD value of about 1.5 Å compared to the docked peptide FSDLYYLTM. 
Similar to the crystal complex, Prime-MMGBSA free energy of binding was lower (better) in both 
the docked complexes (Table 4) and the F pocket was enlarged after the MD simulations 
(Appendix 3, Figure 11.5). Besides, RMSF of residues 2 (Ser) and 9 (Met) of the docked peptide 
FSDLYYLTM in the binding groove is also comparable with the co-crystalized peptide (ALGIGILTV) 
and less than that of peptide MAEVRSYCY (Figure 9.2D). Moreover, RSA of residue 9 in FSDLYYLTM 
and the crystal peptide was also less than that of Tyr9 in MAEVRSYCY. However, P2 (Ser) is more 
solvent accessible in both docked peptides, suggesting a lower affinity of the peptide N-terminus 
than the C-terminus (Figure 10.2D).  
 
PDB ID: 3I6G. When it comes to the the HLA-A*0201 structure in complex with GLMWLSYFV 
peptide (human SARS coronavirus, PDB ID: 3I6G), the number of hydrogen bond interactions 
between the docked peptide and the MHC I binding groove in the two peptide-HLA complexes 
(MAEVRSYCY-HLA-A*0201 and, FSDLYYLTM-HLA-A*0201) increased during the MD simulations 
(Appendix 2E). The largest number of interactions were formed between Glu3 from MAEVRSYCY 
peptide and Arg97 and His114 from the HLA molecule. Trp147 and Asp77 of the MHC I seem to 
be important interaction partners since they retained their hydrogen bonds in the docked 
complexes as well as the experimental complex throughout the MD simulations. RMSD of the 
backbone atoms of the HLA-A*0201 binding groove for the complex with the docked peptide 
FSDLYYLTM had approximately the same value as the complex with the co-crystalised peptide 
GLMWLSYFV (about 1.5 Å), whereas it was larger (about 2 Å) for the complex with MAEVRSYCY 
(Figure 7.2E). On the other hand, RMSD of the backbone atoms for the two predicted peptides 
was approximately the same (1.5 Å ) as it was for the co-crystallised peptide (GLMWLSYFV) (Figure 
8.2E). Prime-MMGBSA free energy of binding worsened for the MAEVRSYCY-HLA-A*0201 
complex from -96.3 to -77.7 kcal/mol during the simulation. By contrast, Prime-MMGBSA free 
energy of binding for the co-crystalized peptide GLMWLSYFV and FSDLYYLTM improved during 
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the MD simulation (Table 4). The F pocket size of all the complexes enlarged during the MD 
simulations (Table 4 and Appendix 3, Figure 11.6). Besides, RMS fluctuation of residues 2 and 9 
of MAEVRSYCY in the binding groove is comparable with the co-crystalized peptide and less than 
that of FSDLYYLTM. The atomic fluctuations of FSDLYYLTM are at lowest at P3 and P8 (Figure 9.2E). 
On the other hand, residues 2 and 9 of FSDLYYLTM have less accessibility to the solvent than the 
same residues of peptide MAEVRSYCY and follow the same trend as co-crystalized peptide (Figure 
10.2E). Consistent with the above analysis, peptide FSDLYYLTM from the ZIKV E protein seems to 
be a stronger binder to the HLA-A*0201 molecule than MAEVRSYCY. 
 
PDB ID: 3TO2. RMSD of the binding groove and the backbone atoms of peptide FSDLYYLTM in the 
HLA-A*0201 structure (PDB ID: 3TO2) were somewhat higher when compared to the MAEVRSYCY-
HLA-A*0201 complex (Figures 7.2F and 8.2F). The two predicted peptides improved their Prime-
MMGBSA free energy of binding during the MD simulations (Table 4). On the other hand, low RSA 
and RMSF of the N-terminal residues (P2-P3) of MAEVRSYCY suggest that only the N-terminus of 
the peptide binds strongly to this MHC I structure (Figures 9.2F and 10.2F and Appendix 3, Figure 
11.7). FSDLYYLTM has a somewhat higher RMSF at P2 but the C-terminal P9 is fluctuating less 
than that of MAEVRSYCY; the anchor residues P2 and P9 of FSDLYYLTM are also well buried. 
However, P3 of FSDLYYLTM is not so buried as the corresponding residues in the co-crystalized 
peptide LACFVLAAV and MAEVRSYCY. As discussed earlier, another measured parameter to 
evaluate the binding affinity of the peptide to the binding cleft is the size of the F pocket that 
accommodates the C-terminus of the nonapeptide. In most complexes, including the 
experimentally determined structures, the size of the F pocket increased somewhat. The 
MAEVRSYCY-HLA-A*0201 complex (PDB ID: 3TO2) was the only one that showed a decrease in 
the F pocket size (Appendix 3, Figure 11.7A) and this seems to result from the fact that the C-
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Figure 7.2. RMSD of the backbone atoms of the MHC I binding groove (residues 1-180) during the 10-ns MD 
simulations of the HLA-A*0201–ZIKV E protein peptide complexes. The ZIKV peptides were docked to the crystal 
structures: A. 1OGA, B. 2GIT, C. 2GTW, D. 2GTZ, E. 3I6G, F. 3TO2, G. 4K7F, and H. 5SWQ. The black line denotes the 
reference peptides bound in the respective crystal structures. 
 
PDB ID: 4K7F. From Figure 7.2G, it can be seen that the HLA-A*0201 (PDB ID: 4K7F) in complex 
with ZIKV E peptide FSDLYYLTM adopted a RMSD value of about 1.2 Å for the backbone atoms of 
the binding groove. The same domain of the crystal complex (VCWGELMNL-HLA-A*0201) and the 
complex with the docked peptide MAEVRSYCY showed a RMSD of about 1.5 Å. On the other hand, 
it can be observed from Figure 8.2G that the lowest peptide RMSD belongs to the co-crystalized 
peptide VCWGELMNL (about 1 Å). This experimental peptide is thus considered as the most stable 
peptide in the binding groove of this HLA-A*0201 structure, which is in line with the low Prime-
MMGBSA energy of the peptide after the MD simulation. On the contrary, the Prime-MMGBSA 
energy for the predicted peptide MAEVRSYCY rose (worsened) from -106.5 to -96.04 kcal/mol 
during the simulation while it again decreased (improved) for peptide FSDLYYLTM (Table 4). The 
F pocket size also enlarged in all the complexes (Table 4; Appendix 3, Figure 11.8). Besides, the 
atomic fluctuations of residues 2 and 9 of FSDLYYLTM and MAEVRSYCY are comparable with the 
co-crystalized peptide. However the fluctuation of residue 9 is higher than that of the co-
crystalized peptide (Figure 9.2G). The relative accessibility of residues 2 and 9 to the solvent was 
below 10 percent for the co-crystalized peptide and FSDLYYLTM. This means that the N-terminus 
(P2) and C-terminus (P9) are deeply buried in the B and F subpockets of the HLA molecule, 
suggesting high binding affinity to the MHC I groove (Figure 10.2G). 
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Figure 8.2A. RMSD of the backbone atoms of the peptides bound to HLA-A*0201 during the 10-ns MD simulations 
of the HLA-A*0201–ZIKV E protein peptide complexes The ZIKV peptides were docked to the crystal structures: A. 
1OGA, B. 2GIT, C. 2GTW, D. 2GTZ, E. 3I6G, F. 3TO2, G. 4K7F, and H. 5SWQ. The black line denotes the reference 
peptides bound in the respective crystal structures. 
 
 
PDB ID: 5SWQ. MD analysis of the HLA-A*0201 molecule (PDB ID: 5SWQ) complexed with the 
docked peptides MAEVRSYCY and FSDLYYLTM revealed that there is an increase in the number of 
H-bond interactions in the binding groove after the MD simulation (Appendix 2H). The extra H-
bonds occurred between Cys1 (N), Asn3 (N) and Val9 (N) of the peptide with Glu63 (OE1, OE2), 
Tyr99 (OH) and Asp77 (OD) of the MHC I molecule. All the newly formed H-bonds are between 
the peptide backbone and the MHC I protein. Tracing the H-bonds for both the docked peptides 
revealed that FSDLYYLTM forms additional H-bonds in the N- and C-terminus at P2 and P9 while 
MAEVRSYCY forms additional H-bonds with residues at P5, P6 and P7. Based on the fact that N- 
and C-terminus are the anchor locations of the peptides when they interact with the MHC I 
binding groove, FSDLYYLTM seems to act as a stronger binder than MAEVRSYCY when regarding 
only the H-bond interactions. RMSD of the backbone atoms of the MHC I binding groove for the 
experimental complex was below 1.5 Å, for FSDLYYLTM about 1.5 Å and for MAEVRSYCY about 
2.0 Å (Figure 7.2H). In addition, RMSD of the peptides was about 1.5 Å for FSDLYYLTM and the 
crystal peptide CVNGSCFTV and 1.7 Å for MAEVRSYCY (Figure 8.2H). The seeming stability of the 
FSDLYYLTM-MHC I complex is also reflected in the value of Prime-MMGBSA energy that decreased 
from -61.87 kcal/mol for the initial docked complex to -101 kcal/mol for the conformation after 
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the MD simulation (Table 4). RMSF of the residues at P9 of FSDLYYLTM and MAEVRSYCY was 1.1 
Å and 1.7 Å, respectively (Figure 9.2H). However, at P2 both peptides showed a value similar to 
that of the co-crystalized peptide, about 1.0 Å. Thus, FSDLYYLTM has less fluctuation at the anchor 
positions P2 and P9, which results in a higher affinity to the B and F pockets, respectively. 
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Figure 9.2. Per-residue RMS fluctuations of the ZIKV E protein peptides in the binding groove of MHC I HLA-A*0201 
during the 10-ns MD simulations. The black line denotes the reference peptide. PDB IDs: A. 1OGA, B. 2GIT, C. 2GTW, 
D. 2GTZ. E. 3I6G, F. 3TO2, G. 4K7F, H. 5SWQ. 
 
 
As mentioned earlier, residues at P2 and P9 are the most important sites for binding to the MHC 
I molecule. In contrast, the other residues (at P4 to P7) are generally more exposed to the solvent 
and interpreted as inactive and low-affinity binders to the MHC I molecule but high-affinity and 
active binders to the T-cell receptors (Höltje et al., 2003). It should be noted that P5 and P7 
(Chapter 2, Figure 3) could bind to both MHC I and TCR. Referring to the peptides FSDLYYLTM and 
MAEVRSYCY in complex with this particular HLA-A*0201 structure, it can be observed that the 
residues at P2, P7 and P9 were completely buried inside the MHC I binding groove (less than 20 
percent of solvent accessibility area) (Figure 10.2H), thus being important for the binding 
interaction. By contrast, the TCR binding residues show a high percentage of solvent accessibility 
(more than 50 percent) for their side chains at P3, P6 and P8. All in all, the above analysis of the 
different HLA-A*0201 crystal structures suggests that FSDLYYLTM would be a stronger binding 








      A                    B 
 
 
      C                   D 
 
 










    G                 H 
 
Figure 10.2. Per-residue relative solvent accessibility of the ZIKV E protein peptides in the binding groove of MHC I 
HLA-A*0201 after the MD simulations. The black line denotes the co-crystalized peptides. PDB IDs: A. 1OGA, B. 2GIT, 
C. 2GTW, D. 2GTZ, E.3I6G, F. 3TO2, G. 4K7F, H. 5SWQ. 
 
Overall, analysing the ZIKV E peptide-HLA-A*0201 complexes and comparing the results with the 
experimentally determined structures of HLA-A*0201, demonstrated that RMSD of the peptide-
binding domain was generally about 1.5 Å in the experimentally determined complexes while this 
value was about 2 Å in the docked peptide-MHC I complexes (Figures 7.2A-H). Yet, RMSD of the 
binding groove in the HLA-A*0201 structures complexed with FSDLYYLTM was usually smaller 
than in the structures complexed with MAEVRSYCY. There were only two exceptions: MAEVRSYCY 
complexes with PDB ID: 1OGA and 3TO2 (Figures 7.2A and F). This indicates that the HLA-A*0201 
complexes with the docked peptide FSDLYYLTM are more stable. On the other hand, RMSD of the 
backbone atoms of the peptide bound to HLA-A*0201 during the 10-ns MD simulation was 
variable in the different structures. In the structures PDB ID: 1OGA and 3TO2 (Figures 7.2A and F) 
FSDLYYLTM had the greatest RMSD, whereas in the structures PDB ID: 2GIT, 4K7F and 5SWQ, 
MAEVRSYCY adopted the greatest RMSD value (Figures 7.2B, G, H).  
Generally, the Prime-MMGBSA energy for the peptide-HLA-A*0201 complexes was 
improved during the MD simulations. However, for example for the MAEVRSYCY-HLA-A*0201 
(PDB ID: 4K7F) complex the energy increased 10 kcal/mol (from -106.59 to -96.06 kcal/mol) which 
is compatible with the higher value of RMS deviation in the complex. However, despite the higher 
RMSD, there is a decrease in the Prime-MMGBSA energy in the MAEVRSYCY-HLA-A*0201 
complexes PDB ID: 2GIT and 5SWQ. Consequently, the RMSD may not always indicate loose 
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binding but only the adaptation of the docked peptide to the binding pocket. Meanwhile, Prime-
MMGBSA energy for FSDLYYLTM complexes was improved (decreased) in all cases. For example, 
FSDLYYLTM complexed with PDB IDs: 1OGA and 4K7F was well-buried via P1, P2 and P3 (Figures 
10.2A, G) and in those cases the binding energy decreased (improved) about 50 kcal/mol. 
Although all MHC I HLA-A*0201 structures complexed with the predicted peptide FSDLYYLTM 
retained some of their initial hydrogen bonds after the MD simulations, this is the most notable 
with four H-bonds in the complexes with PDB ID: 2GTW and PDB ID: 3I6G (Appendices 2C and E). 
All the studied HLA-A*0201 complexes formed more H-bond interactions with FSDLYYLTM 
compared to MAEVRSYCY. 
As mentioned earlier, in only one of the HLA-A*0201 complexes the F pocket size reduced 
during  the MD simulation (MAEVRSYCY with PDB ID: 3TO2, Table 4), whereas in all other 
predicted as well as the experimentally determined peptide-MHC I complexes the groove 
widened somewhat at the pocket F region (Table 4; Appendix 3, Figures 11.1-11). Also, Prime-
MMGBSA binding energy was generally reduced with some exceptions (Table 4). The reason for 
the exceptions could be for example a loss of some particular hydrogen bonding interaction in 
the docked peptide-MHC I complexes. However, one should bear in mind that the value of Prime-
MMGBSA free energy of binding is comprised of many components such as Coulomb energy, van 
der Waals energy, lipophilic energy, pi-pi packing energy, Generalized Born electrostatic solvation 
energy as well as hydrogen-bonding energy. The Prime-MMGBSA ΔG(bind), the binding free 
energy is calculated as follows (Eq. 1) (Li et al., 2011): 
 
ΔG(bind) = E_complex[minimized] - (E_ligand[minimized] + E_receptor[minimized]) Eq.1 
It is based on the calculation of five fundamental energies, namely: 
 Optimized free receptor 
 Optimized free ligand  
 Optimized complex  
 Receptor from minimized/optimized complex 
 Ligand from minimized/optimized complex 
 The improved Prime-MMGBSA energy indicates that most of the docked peptides adopted a 
better pose during the simulation (exceptions: MAEVRSYCY complexed with PDB ID: 2GTW, 3I6G, 
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and 4K7F). All but one (3TO2) of the experimentally determined HLA-A*0201 complexes show at 
least a slight improvement in their Prime-MMGBSA energy after the MD simulations. 
 Fleishman et al. (2015) suggested that low-affinity peptides widen the peptide-MHC I 
binding groove and that the groove will be tightened by high-affinity peptides (Fleishman et al., 
2015). The strong disulfide bonds between Cys101 from the α2 helix and Cys164 from the β-sheet 
reinforce the stability of the B pocket while the F pocket lacks such bonds, leading to increased 
flexibility of this region (Zacharias & Springer, 2004). Thus, it was suggested that the F pocket size 
could help recognize the tight binding peptides (Abualrous et al., 2015). This study shows that 
only one of the predicted peptides with high Prime-MMGBSA energy reduced the F pocket size, 
whereas most predicted peptides and the crystal peptides with the high Prime energy widen the 
F pocket. Thus, we can draw a conclusion that the F pocket size may not be a decisive criterion to 
determine the degree of binding affinity of the peptide to the binding groove.  
 
5.3.3 HLA-B*2705 in complex with ZIKV NS3 protein peptides 
 
In this section, we will review the MD analysis of the MHC I HLA-B*2705 (PDB ID: 2BST) complexes 
with the predicted antigenic peptides from the ZIKV NS3 protein (DIGAVALDY and HSEVQLLAV) 
and the experimental peptide SRYWAIRTR (Influenza A virus peptide). Results from the MD 
analysis are presented in Tables 2B and 4, Figures 7.3, 8.3, 9.3, 10.3 and Appendix 3: Figure 11.10). 
H-bond interaction analysis revealed that Glu45, Glu63 and Asp77 are the most important 
residues to sustain the hydrogen bonding network in the HLA-B*2705 complexes before and after 
the MD simulations (see Table 2B). While the MD simulation resulted in fewer H-bonds in the 
DIGAVALDY-HLA-B*2705 complex, the number of H-bonds increased in the HSEVQLLAV-HLA-
B*2705 complex. The greatest number of H-bonds was formed by His1 in the HSEVQLLAV-HLA-
B*2705 complex. RMSD of the backbone atoms of the MHC I binding groove was approximately 
1.5 Å and 1.7 Å for the HSEVQLLAV-HLA-B*2705 and DIGAVALDY-HLA-B*2705 complexes, 
respectively (Figure 7.3). RMSD of the backbone atoms of the peptide bound to HLA-B*2705 rises 
up to about 2.0 Å for the docked peptides while the experimentally verified antigenic peptide 
(SRYWAIRTR) had a RMSD value of only 1.2 Å, being the most stable peptide in the groove during 





Figure 7.3. RMSD of the backbone atoms of the MHC I binding groove (residues 1-180 in PDB ID: 2BST) during the 
10-ns MD simulation of the ZIKV NS3 peptide-HLA-B*2705 complexes. The black line denotes the reference peptide. 
 
 
Figure 8.3. RMSD of the backbone atoms of the ZIKV NS3 peptides (green and red lines) and the reference peptide 
(black line) bound to HLA-B*2705 (PDB ID: 2BST) during the 10-ns MD simulation. 
 
RMSF of the peptide residues and per-residue RSA were also measured for the crystal complex as 
well as the docked peptide-HLA-B*2705 complexes (Figures 9.3 and 10.3). RMSF of the residues 
at P2 of HSEVQLLAV and DIGAVALDY rises almost over 1.2 Å, which indicates relatively large 
flexibility at the binding site (few interactions from the peptide to the pocket). RMSF is 
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dramatically higher for the residue 9 in both peptides, which indicates that large flexibility and 
movement of the C-terminus of the peptide does not allow for a tight binding to the groove. The 
low fluctuations of the co-crystalized peptide SRYWAIRTR emphasize the tight and stable binding 
of the anchor residues to the binding groove. The relative accessibility of the DIGAVALDY residues 
to the solvent follows the RSA pattern of the co-crystalized peptide but is higher at the anchor 
positions P2 and P9 (30-40 % vs 1-7 %). The RSA at the anchor positions in HSEVQLLAV is 
comparable with DIGAVALDY (31-36 %). On the other hand, P7 and P8 from peptide HSEVQLLAV 
have lower accessibility to the TCR, which might affect the ability of the peptide to stimulate the 
immune system (Figure 10.3). 
 
 
Figure 9.3. Per-residue RMS fluctuations of the ZIKV NS3 protein peptides the binding groove of MHC I HLA-B*2705 






Figure 10.3. Per-residue relative solvent accessibility of the ZIKV NS3 protein peptides in the binding   groove of 
MHC I HLA-B*2705 (PDB ID: 2BST; the black line denotes the reference peptide) after the MD simulations. 
 
The F pocket size in both ZIKV NS3 peptide-MHC I complexes was smaller before the MD 
simulations than after MD as defined by the distances (d) between the alpha carbon atoms of 
residues 85 and 138 (d1) and residues 74 and 149 (d2) (see Table 4, Figure 11.1.D). The Prime-
MMGBSA free energy of binding for the peptides was poor(-43.90 kcal/mol and -31.32 kcal/mol 
for DIGAVALDY and HSEVQLLAV, respectively) and did not improve much during the simulations 
(Table 4). The above analysis suggests that neither of the predicted peptides is a strong binder at 
HLA-A*B2705. However, DIGAVALDY seems to be somewhat more stable particularly within the 
F pocket, probably due to the rigidity of Tyr9 compared to Val9 of HSEVQLLAV. It also has a more 
solvent-exposed stretch in the central area to be recognized by TCR. 
 
5.3.4 HLA-C*0801 in complex with ZIKV NS5 protein peptides 
 
The results of the MD analysis of the HLA-C*0801 molecule (PDB ID: 4NT6) complexed with ZIKV 
NS5 peptides MTTEDMLVV and FTNLVVQLI are reviewed in this section. Both docked peptides 
kept some of their initial H-bonds in the binding groove and the number of H-bonds for both the 
predicted and the crystal peptide-MHC I complexes rose during the simulations (Table 2C). This 
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rise is more observable for FTNLVVQLI than MTTEDMLVV. Among the residues of the MHC I HLA-
C*0801 binding groove, Trp147 (NE1 atom) plays a crucial role as it forms a hydrogen bond 
interaction to the peptide C-terminus in both the docked complexes and the crystal before and 
after the MD simulations. In addition, one clash was found between Thr2 of MTTEDMLVV and 
Tyr9 of the MHC I binding groove before MD (Table 3), suggesting that FTNLVVQLI would be a 
better fitting peptide to the MHC I binding groove compared to MTTEDMLVV. However, both 
docked peptides showed equal improvement in the Prime-MMGBSA energy (Table 4). 
MTTEDMLVV had a lower RMSD value (1.7 Å) for the binding groove compared to that of 
FTNLVVQLI (2.0 Å; Figure  7.4). Besides, RMSD of the backbone atoms of the peptides during the 
10-ns MD simulation rose up to about 1.5 Å for the docked peptides, whereas it was only about 
0.5 Å for the co-crystalised peptide GILGFVFTL (Figure  8.4). 
 
Figure 7.4.  RMSD of the backbone atoms of the MHC I binding groove (residues 1-180 in PDB ID: 4NT6) during the 







Figure 8.4. RMSD of the backbone atoms of the ZIKV NS5 peptides (green and red lines) and the reference peptide 
(black line) bound to HLA-C*0801 (PDB ID: 4NT6) during the 10-ns MD simulations. 
 
 
Per-residue RMSF of the ZIKV NS5 peptides in the binding groove of the MHC I HLA-C*0801 
demonstrates less fluctuation in the N-terminus of FTNLVVQLI and the C-terminus of 
MTTEDMLVV (Figure 9.4). The fluctuations at P2 rise up to about 1.2 Å for FTNLVVQLI and about 
1.8 Å for MTTEDMLVV. This means that the flexibility of especially MTTEDMLVV in the peptide-
binding domain is high, which results in a less stable peptide-MHC I complex (few interactions 
from the peptide to the pocket). Therefore, it is likely that MTTEDMLVV is not a strong binder to 
HLA-A*0801 (and not a suitable vaccine candidate if it cannot bind to any other HLA molecules 
either). It should be also mentioned that the F pocket enlarged in the crystal complex as well as 
the docked peptide-HLA-C*0801 complexes. 
Measured per-residue RSA profile for the docked peptide-HLA-C*0801 complexes shows 
that MTTEDMLVV follows the RSA profile of the crystal peptide, suggesting that the anchor 
residues at P2 and P9 have a stronger binding affinity to the MHC I and residues at P4-P6 to the 
TCR. However, both the docked peptides have overall much greater per-residue RSA values than 





Figure 9.4. Per-residue RMS fluctuations of the ZIKV NS5 protein peptides in the binding groove of MHC I HLA-C*0801 




Figure 10.4. Per-residue relative solvent accessibility of the ZIKV NS5 protein peptides in the binding groove of MHC 
I HLA-C*0801 (PDB ID: 4NT6, the black line denotes the reference peptide) after the MD simulations. 
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Table 4. Dynamics and energetics of the ZIKV peptide-MHC I complexes (experimental 
complexes are denoted in italics) 
 









Change in the MHC I 
binding groove 













 Antigenic epitopes from ZIKV E protein bound to MHC I HLA-A*0101 
TMNNKHWLV 0.889 9.44/20.76 9.18/22.8 -136.607 -108.447 
GLDFSDLYY 0.93 9.44/20.70 12.44/20.98 -133.661 -152.772 
CTELKLSDY 1.24 9.74/20.73 10.15/21.76 -107.604 -133.745 
 
1OGA 
Antigenic epitopes from ZIKV E protein bound to MHC I HLA-A*0201 
MAEVRSYCY 0.882 9.6/20.03 10.43/21.02 -91.53 -68.74 
 FSDLYYLTM 1.06 9.6/20.3 9.11/21.45 -61.36 -117.156 
GILGFVFTL 0.85 9.6/20.3 12.34/20.52 -104.87 -123.38 
 
2GIT 
MAEVRSYCY 0.995 9.43/20.02 12.1/22.8 -79.307 -88.785 
 FSDLYYLTM 1.55 9.7/20.37 10.6/20.26  -85.650  -97.445 
LLFGKPVYV 0.607 9.32/20.21 11.53/19.94 -106.223 -118.193 
       
2GTW 
MAEVRSYCY 1.32 9.55/19.73 12.44/21.32 -44.874 -11.917 
 FSDLYYLTM 1.07 9.53/19.72 11.24/19.72 -35.543 -125.471 
LAGIGILTV 0.750 9.55/19.72 12.33/21.26 -69.1 -90.817 
 
2GTZ 
MAEVRSYCY 0.992 9.42/20.03 11.73/23.3 -33.27 -78.04 
 FSDLYYLTM 1.35 9.43/19.95 13.8/22.53 -59.34 -86.76 
ALGIGILTV  1.167 9.57/19.58 10.35/20.55 -80.90 -86.016 
   
3I6G 
MAEVRSYCY 0.992 9.87/19.72 11.96/21.15 -96.39 -74.76 
 FSDLYYLTM 0.913 9.87/19.72 12.08/21.19 -86.03 -131.405 
GLMWLSYFV 0.925 9.87/19.72 11.36/20.95 -97.66 -131.89 
  
3TO2 
MAEVRSYCY 1.2 10.16/19.9 9.46/19.76c -69.93 -105.27 
 FSDLYYLTM 1.15 10.16/19.9 12.05/21.27 -56.63 -117.49 
LACFVLAAV 0.926 9.87/19.72 10.91/21.08 -92.09 -90.72 
 
4K7F 
MAEVRSYCY 0.954 10.51/20.44 12.09/21.79 -106.59 -96.04 
 FSDLYYLTM 1.32 10.51/20.44 11.34/22.11 -66.78 -112.79 





MAEVRSYCY 0.981 9.88/20.19 12.5/21.44 -70.95 -90.20 
 FSDLYYLTM 0.676 9.88/20.19 11.42/21.66 -61.87 -101.26 
CVNGSCFTV 0.757 9.878/20.19 10.28/19.3 -82.27 -110.170 
 
2BST 
Antigenic epitopes from ZIKV NS3 protein bound to MHC I HLA-B*2705 
DIGAVALDY 1.135 9.5/20 12.36/20.08 -43.90 -66.83 
HSEVQLLAV 1.1 9.5/20   13.52/18.96 -31.32 -44.06 
SRYWAIRTR 1.02 9.5/20 10.41/20.54 -118.37 -169.418 
 
4NT6 
Antigenic epitopes from ZIKV NS5 protein bound to MHC I HLA-C*0801 
MTTEDMLVV 1.17 9.19/19.63 10.24/20.86 -86.06 -101.112 
FTNLVVQLI 0.679 9.19/19.63 14.55/19.8 -62.06 -86.14 
GILGFVFTL 0.373 9.19/19.63 11.71/20.44 -127.25 -129.59 
a RMSD of the Cα atoms between the initial docked peptide conformation and the minimized conformation from the 
final MD frame; bd1=distance between the Cα atom of Tyr85 in α1 helix and Met138 in α2 helix (Thr138 in HLA-
B*2705 and HLA-C*0801); d2=distance between the Cα atom of Asp74 in α1 helix and Ala149 in α2 helix (Tyr74 in 






Regarding the recent outbreak of ZIKV infection, urgent action is needed to develop a preventive 
or a therapeutic ZIKV vaccine. This project employed computational methods such as docking and 
MD simulations to evaluate the binding affinity of candidate T-cell epitope peptides of ZIKV 
proteins to the MHC class I molecules. 
MHC I alleles HLA-A*0101, HLA-A*0201, HLA-B*2705 and HLA-C*0801 were used as 
receptor structures and eight different peptides from ZIKV proteins (E, NS3, NS5) were docked at 
these MHC I molecules (see Chapter 4). The initial PDB structures were prepared with the Protein 
Preparation Wizard tool implemented in Maestro. Residues of the experimental peptide were 
mutated to the residues in the desired ZIKV peptide with Chimera. Next, mutated peptide-MHC I 
complexes were submitted to the FlexPepDock tool to refine the geometry of the complex 
structures and remove the atomic clashes that resulted from the manual docking. All the docked 
peptide-MHC I complexes from FlexPepDock were submitted to MD simulation for further 
refinement along with the experimentally determined peptide-MHC I complexes to examine and 
compare their stability. The MD simulations were performed in an explicit TIP3P water model at 
300 K and at 1 bar pressure for 10 ns. Na+ ions were used for neutralizing the simulation system. 
Multiple parameters were measured to analyze the binding strength of the peptides to 
the MHC I molecules such as: hydrogen bonding network, RMSD for both the backbone atoms of 
the MHC I peptide-binding domain and the peptides, atomic fluctuations of the peptide residues, 
per-residue SASA of the peptides, Prime-MMGBSA free energies of binding and the size of the F 
pocket before and after the MD simulations. Among all, RMSF (atomic fluctuation) and atomic 
solvent accessibility play crucial roles in the evaluation of the peptide affinity to the MHC I. It has 
been argued that the calculation of interaction energies should not have a decisive role in 
predicting the peptide affinity since the potentials used for the calculations are generally 
approximations and for example the hydrophobic effect has been neglected in many cases (Höltje 
et al., 2003). However, Prime-MMGBSA free energy calculation may be a more accurate method 
as it includes the lipophilic energy and solvation effects and thus, it can be useful in at least 
comparing the different peptides and providing an estimate on any likely favorable interactions.  
To sum up, the hydrogen bonding network of crystal structures could be partially 
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regenerated for the docked structures as well. Although there were some differences in the 
hydrogen bonding patterns, low-affinity binders could be generally recognized by the loss of H-
bond interactions compared to the better binders and especially the co-crystalized peptides. 
There was a considerable change in the hydrogen bonding network regenerated for some crystal 
complexes and almost all docked complexes after the MD simulation. Generally, it can be said 
that the binding affinity of the peptide highly correlates to the number of hydrogen bonds 
between the peptide (particularly its N- and C-terminus) and the MHC I molecule. In addition, all 
crystal structures retained some of the initial H-bonds after the MD simulation. Besides, despite 
some steric clashes in the docked complexes before the MD simulation, these conflicts were 
removed via forming new favorable hydrogen bond interactions during the MD simulations (Table 
3). Overall, the complexes get stabilized during the MD simulation. 
Since the fluctuation of the peptide directly depends on its binding interactions, 
measuring the atomic fluctuations of the peptide residues provides a good insight into the ligand 
activity-related properties on (Höltje et al., 2003). In this regard, calculating the fluctuations of 
the docked peptides and comparing them to the fluctuations of the co-crystalized peptides gives 
possibilities to evaluate and understand the degree of flexibility of the docked peptide. One 
should bear in mind that not only the degree of burial of the peptide residues in the 
corresponding MHC I pockets is crucial, but the docking pose of the peptide is of importance as 
well. This means that sometimes the docked peptides can adopt bulged or even helical 
conformation rather than an extended pose, which is not the proper geometry to stimulate the 
TCR. Although some peptides seemed to interact with the MHC I molecule via the residues 
between P4 to P7, most of the interactions formed between the peptide N- and C-terminus, which 
supports the well-known pattern of the peptide-MHC I complex to elicit a cellular immune 
response.  
Our study concluded that the changes in the size of the F pocket as a decisive criterion to 
determine the binding affinity of the peptide to the MHC molecule is arguable. In this regard, we 
refer to the finding by Zakharias and Springer (2004) who suggest that the binding of the C-
terminal segment of the peptide to the F pocket may require stabilization by a chaperon protein 
during the peptide loading (Zacharias & Springer, 2004). 
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Considering the sequence variability analysis of the MHC I molecules and also the analysis of the 
degree of affinity of the peptide to the binding groove of the MHC I molecule, this study reveals 
that each allelic polymorphism in the MHC I molecules (particularly in the peptide binding site) 
has a substantial effect on the binding affinity of the peptide to the MHC I peptide-binding 
domain. Moreover, in a research conducted by Reche and Reinherz (2003) where they 
investigated the sequence variability and peptide/TCR contacts in the peptide-binding domain of 
the MHC I (α1 and α2 domains), the result indicated that almost all residues that are in contact 
with TCR are in the proximity of the peptide (< 5 Å). In addition, the diversity of the residues in 
the α3 domain (CD8+ binding domain), especially in position 225-232 belongs to the motifs that 
are in contact with the CD8+ co-receptor. This co-receptor assists with the stability of the overall 
complex when peptide-MHC I is connected to TCR (Margulies, 1997). Accordingly, it can be 
concluded that the affinity of the peptides to the MHC I (the scope of this study) is not the only 
contributing factor for the immunogenesis. The affinity of MHC I molecules to CD8+ in α3 domain, 
as well as the affinity of the peptide-MHC I complex to the TCR in α1 and α2 domains should also 
be taken into account when measuring the immunogenicity of the peptide-MHC I complexes. 
The final results demonstrated that the two predicted peptides, GLDFSDLYY and 
FSDLYYLTM, exhibited the highest affinity to the studied MHC I alleles (HLA-A*0101 and HLA-
A*0201). However, the rest of the studied ZIKV peptides seem not to bind strongly to the 
respective MHC I molecules used in the study. 
Finally, the study showed that in silico approach can be used as an effective and fast 
method to predict candidate peptides for vaccine design and at the same time the approach 
reduces the number of in vitro experiments. As a suggestion for future study, other peptides could 
also be studied in a similar way for their binding affinity. Meanwhile, the peptides could also be 
studied using different docking tools to investigate their binding affinity for the same, or other, 
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Appendix 1. Multiple Sequence Alignment of HLA-MHC I molecules 
 
              *        20         *        40         *        60       
HLA-A-29 : GSHSMRYFTTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-A-25 : GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-A-32 : GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-A-2  : GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-A-1  : GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQKMEPRAPWIEQEGPEYW :  60 
HLA-A-11 : GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-A-3  : GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYW :  60 
HLA-Cw-1 : CSHSMKYFFTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPRGEPRAPWVEQEGPEYW :  60 
HLA-Cw-2 : CSHSMRYFYTAVSRPSRGEPHFIAVGYVDDTQFVRFDSDAASPRGEPRGRWVEQEGPEYW :  60 
HLA-Cw-3 : GSHSMRYFYTAVSRPGRGEPHFIAVGYVDDTQFVRFDSDAASPRGEPRAPWVEQEGPEYW :  60 
HLA-Cw-4 : GSHSMRYFSTSVSWPGRGEPRFIAVGYVDDTQFVRFDSDAASPRGEPREPWVEQEGPEYW :  60 
HLA-Cw-8 : CSHSMRYFYTAVSRPGRGEPRFIAVGYVDDTQFVQFDSDAASPRGEPRAPWVEQEGPEYW :  60 
HLA-Cw-5 : CSHSMRYFYTAVSRPGRGEPRFIAVGYVDDTQFVQFDSDAASPRGEPRAPWVEQEGPEYW :  60 
HLA-B-57 : GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRMAPRAPWIEQEGPEYW :  60 
HLA-B-44 : GSHSMRYFYTAMSRPGRGEPRFITVGYVDDTLFVRFDSDATSPRKEPRAPWIEQEGPEYW :  60 
HLA-B-35 : GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRTEPRAPWIEQEGPEYW :  60 
HLA-B-27 : GSHSMRYFHTSVSRPGRGEPRFITVGYVDDTLFVRFDSDAASPREEPRAPWIEQEGPEYW :  60 
HLA-B-40 : GSHSMRYFHTSVSRPGRGEPRFITVGYVDDTLFVRFDSDATSPRKEPRAPWIEQEGPEYW :  60 
HLA-B-7  : GSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYW :  60 
HLA-B-8  : GSHSMRYFDTAMSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYW :  60 




                    *        80         *       100         *       120       
HLA-A-29 : DLQTRNVKAQSQTDRANLGTLRGYYNQSEAGSHTIQMMYGCHVGSDGRFLRGYRQDAYDG : 120 
HLA-A-25 : DRNTRNVKAHSQTDRESLRIALRYYNQSEDGSHTIQRMYGCDVGPDGRFLRGYQQDAYDG : 120 
HLA-A-32 : DQETRNVKAHSQTDRESLRIALRYYNQSEAGSHTIQMMYGCDVGPDGRLLRGYQQDAYDG : 120 
HLA-A-2  : DGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDG : 120 
HLA-A-1  : DQETRNMKAHSQTDRANLGTLRGYYNQSEDGSHTIQIMYGCDVGPDGRFLRGYRQDAYDG : 120 
HLA-A-11 : DQETRNVKAQSQTDRVDLGTLRGYYNQSEDGSHTIQIMYGCDVGPDGRFLRGYRQDAYDG : 120 
HLA-A-3  : DQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDG : 120 
HLA-Cw-1 : DRETQKYNRQAQTDRVSLRNLRGYYNQSEAGSHTLQWMCGCDLGPDGRLLRGYDQYAYDG : 120 
HLA-Cw-2 : DRETQKYNRQAQTDRVNLRKLRGYYNQSEAGSHTLQRMYGCDLGPDGRLLRGYDQSAYDG : 120 
HLA-Cw-3 : DRETQKYKRQAQTDRVSLRNLRGYYNQSEAGSHIIQRMYGCDVGPDGRLLRGYDQYAYDG : 120 
HLA-Cw-4 : DRETQKYKRQAQADRVNLRKLRGYYNQSEDGSHTLQRMFGCDLGPDGRLLRGYNQFAYDG : 120 
HLA-Cw-8 : DRETQKYKRQAQTDRVSLRNLRGYYNQSEAGSHTLQRMYGCDLGPDGRLLRGYNQFAYDG : 120 
HLA-Cw-5 : DRETQKYKRQAQTDRVNLRKLRGYYNQSEAGSHTLQRMYGCDLGPDGRLLRGYNQFAYDG : 120 
HLA-B-57 : DGETRNMKASAQTYRENLRIALRYYNQSEAGSHIIQVMYGCDVGPDGRLLRGHDQSAYDG : 120 
HLA-B-44 : DRETQISKTNTQTYRENLRTALRYYNQSEAGSHIIQRMYGCDVGPDGRLLRGYDQDAYDG : 120 
HLA-B-35 : DRNTQIFKTNTQTYRESLRNLRGYYNQSEAGSHIIQRMYGCDLGPDGRLLRGHDQSAYDG : 120 
HLA-B-27 : DRETQICKAKAQTDREDLRTLLRYYNQSEAGSHTLQNMYGCDVGPDGRLLRGYHQDAYDG : 120 
HLA-B-40 : DRETQISKTNTQTYRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDG : 120 
HLA-B-7  : DRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDG : 120 
HLA-B-8  : DRNTQIFKTNTQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDG : 120 




                    *       140         *       160         *       180       
HLA-A-29 : KDYIALNEDLRSWTAADMAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQ : 180 
HLA-A-25 : KDYIALNEDLRSWTAADMAAQITQRKWETAHEAEQWRAYLEGRCVEWLRRYLENGKETLQ : 180 
HLA-A-32 : KDYIALNEDLRSWTAADMAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQ : 180 
HLA-A-2  : KDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQ : 180 
HLA-A-1  : KDYIALNEDLRSWTAADMAAQITKRKWEAVHAAEQRRVYLEGRCVDGLRRYLENGKETLQ : 180 
HLA-A-11 : KDYIALNEDLRSWTAADMAAQITKRKWEAAHAAEQQRAYLEGRCVEWLRRYLENGKETLQ : 180 
HLA-A-3  : KDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQ : 180 
HLA-Cw-1 : KDYIALNEDLRSWTAADTAAQITQRKWEAAREAEERRAYLEGTCVEWLRRYLENGKESLQ : 180 
HLA-Cw-2 : KDYIALNEDLRSWTAADTAAQITQRKWEAAREAEEWRAYLEGECVEWLRRYLENGKEKLQ : 180 
HLA-Cw-3 : KDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQLRAYLEGLCVEWLRRYLKNGKETLQ : 180 
HLA-Cw-4 : KDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGTCVEWLRRYLENGKETLQ : 180 
HLA-Cw-8 : KDYIALNEDLRSWTAADTAAQITQRKWEAARTAEQLRAYLEGTCVEWLRRYLENGKKTLQ : 180 
HLA-Cw-5 : KDYIALNEDLRSWTAADKAAQITQRKWEAAREAEQRRAYLEGTCVEWLRRYLENGKKTLQ : 180 
HLA-B-57 : KDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYLEGLCVEWLRRYLENGKETLQ : 180 
HLA-B-44 : KDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQDRAYLEGLCVESLRRYLENGKETLQ : 180 
HLA-B-35 : KDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYLEGLCVEWLRRYLENGKETLQ : 180 
HLA-B-27 : KDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYLEGECVEWLRRYLENGKETLQ : 180 
HLA-B-40 : KDYIALNEDLRSWTAADTAAQITQRKWEAARVAEQLRAYLEGECVEWLRRYLENGKETLQ : 180 
HLA-B-7  : KDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLE : 180 
HLA-B-8  : KDYIALNEDLRSWTAADTAAQITQRKWEAARVAEQDRAYLEGTCVEWLRRYLENGKDTLE : 180 




                    *       260         *       280         *       300       
HLA-A-29 : FQKWASVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAV-FA : 299 
HLA-A-25 : FQKWASVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAV-IA : 299 
HLA-A-32 : FQKWASVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAM-FA : 299 
HLA-A-2  : FQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAV-IT : 299 
HLA-A-1  : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAV-IT : 299 
HLA-A-11 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAV-IT : 299 
HLA-A-3  : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAV-IT : 299 
HLA-Cw-1 : FQKWAAVMVPSGEEQRYTCHVQHEGLPEPLTLRWEPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-Cw-2 : FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWEPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-Cw-3 : FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWEPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-Cw-4 : FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWKPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-Cw-8 : FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWGPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-Cw-5 : FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLTLRWGPSSQPTIPIVGIVAGLAVLAVLAVL : 300 
HLA-B-57 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 
HLA-B-44 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 
HLA-B-35 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTIPIVGIVAGLAVLAVV-VI : 299 
HLA-B-27 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 
HLA-B-40 : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 
HLA-B-7  : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 
HLA-B-8  : FQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVV-VI : 299 




                    *       320         *       340         
HLA-A-29 : GAVVAAVRWRRKSSDRKGGSYSQAASSDSAQGSDMSLTACKV : 341 
HLA-A-25 : GAVVAAVMWRRKSSDRKGGSYSQAASSDSAQGSDMSLTACKV : 341 
HLA-A-32 : GAVVAAVRWRRKSSDRKGGSYSQAASSDSAQGSDMSLTACKV : 341 
HLA-A-2  : GAVVAAVMWRRKSSDRKGGSYSQAASSDSAQGSDVSLTACKV : 341 
HLA-A-1  : GAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV : 341 
HLA-A-11 : GAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV : 341 
HLA-A-3  : GAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV : 341 
HLA-Cw-1 : GAVVAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIASKA : 342 
HLA-Cw-2 : GAVVAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIASKA : 342 
HLA-Cw-3 : GAVVAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIACKA : 342 
HLA-Cw-4 : GAMVAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIACKA : 342 
HLA-Cw-8 : GAVMAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIACKA : 342 
HLA-Cw-5 : GAVMAVVMCRRKSSGGKGGSCSQAASSNSAQGSDESLIACKA : 342 
HLA-B-57 : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 
HLA-B-44 : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 
HLA-B-35 : GAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTA--- : 338 
HLA-B-27 : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 
HLA-B-40 : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 
HLA-B-7  : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 
HLA-B-8  : GAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA--- : 338 




Appendix 2A. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 1OGA) complexes. 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 










db init dc MD db init dc MD db init dc MD 
P1(N) GLU 63 OE1   * 2.704 
 
        
GLU 63 OE2 
 
          * 2.685 
TYR 7  OH     * 2.890       
P1(O) TYR1 59 OH 
 
* 2.766 * 2.649 * 3.011 
 
      
TYR 7 OH           * 2.774 
P2(N) GLU 63 OE1 
 
* 2.934 * 2.805     * 2.934   
P2(O) LYS 66 NZ 
 
* 2.799 * 2.999     * 2.799   
TYR 99 OH           * 2.777 
P2(OG) HIS 70 NE2           * 2.913 
GLU 63 OE1           * 2.521 
P3(N) TYR 99 OH 
 
  * 3.300         
P3(OE1) ARG 97 NH1       * 3.368     
P3(OD1) ARG 97 NH1           * 3.169 
P3(OD2) ARG 97 NH2           * 2.911 
P3(OE2) ARG 97 NH1       * 2.802     
P3(O) HIE 70 NE2   * 2.799 * 2.900       
P4(O) LYS 66 NZ     * 2.909       
P6(OG) THR 73 OG1     * 2.842       
P6(OH) THR 73 OG1           * 2.953 
ASP 77 OD2           * 2.658 
P7(O) THR 73 OG1       * 2.986     
P7(OH) TYR 116 OH     * 2.701       
P8(O) TRP 147 NE1 
 
* 2.874 * 2.991 * 2.871     * 2.837 
LYS 146 NZ * 3.322 * 2.786         
P9(N) ASP 77 OD1 * 2.880 * 2.773 * 2.941       
ASP 77 OD2           * 3.005 
P9(O) THR 143 OG1 
 
  * 2.736 
 
        
LYS 146.A NZ 
 
          * 2.808 
P9(OXT) LYS 146 NZ 
 
* 3.009           
THR 80  OG1           * 2.719 
Total no of interactions 7  10  8  3  2  13  
Side chain interactions -  _ 
 
 2  2  _  6  
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Appendix 2B.  Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 2GIT) complexes. 
 
 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 










dbinit dcMD dbinit dcMD dbinit dcMD 
P1(N) GLU 63 OE1   * 2.938         
TYR 171  OH 
 
* 2.951   
 





GLU 63 OE2 
 
  * 2.779   * 2.751   * 2.713 
TYR 7  OH         * 2.915   
P1(O) TYR159 OH 
 
* 2.758 * 2.782         






        
GLU 63 OE2 * 3.003 * 2.908 * 2.916   * 3.018   
P2(O) LYS66 NZ 
 
    * 2.887   * 2.823   
P2(OG) GLU 63 OE2           * 2.675 
P3(N) TYR 99 OH 
 
* 3.028 * 3.394 * 3.016   
 
* 3.024   
HID 70 NE2       * 3.172     
P3(OE2) HID 114  ND1     * 3.178       
P5(NH1) GLN 155 O       * 3.025     
P6(O) THR 73 OG1     * 3.219       
P6(OG) ARG 97 NH2       * 2.926     
P7(O) ARG 97 NH1     * 3.286       
P7(OH) GLN 155 OE1     * 3.145       
P8(O) TRP147 NE1 
 
* 2.818   * 2.923 * 2.880 
 
* 2.892 * 2.926 
LYS 146 NZ       * 2.951     
P8(OG1) ASP 77 OD1           * 2.650 
 
P9(N) ASP 77 OD1 * 3.046 * 2.833 * 3.397   * 2.915 * 2.965 



















LYS 146 NZ 
 
          * 2.887 
THR 143 OG1 * 
 
3.502 * 2.855       * 2.635 
P9(OH) ASP 77 OD2       * 2.721     
P9(OXT) LYS146 NZ 
 
* 2.884 * 2.906   * 2.905 * 2.847   
TYR 84 OH 
 
    * 2.798       
THR 143  OG1     * 2.763       
Total no of interactions 11  9  12  9  10  7  
Side chain interactions _  _ 
 
 2  2  _  2  
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Appendix 2C. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 2GTW) complexes. 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 









dbinit dcMD dbinit dcMD dbinit dcMD 
P1(N) GLU 63 OE1   * 3.536   * 2.750     
GLU 63 OE2 
 
* 3.100 * 2.699 * 3.100   * 3.100 * 2.696 
P1(O) LYS 66 NZ * 2.951   * 2.951   * 2.950 * 2.832 
P2(O) HIS 70 NE2       * 2.866   * 2.773 
P2(OG) TYR 99 OH 
 
          * 2.910 
P5 (O) HIS 114 NE2   * 2.994         
P6(O) THR 73 OG1       * 2.614   * 2.640 
P7(O) ARG 97 NH1 * 3.216 * 3.078 * 3.216   * 3.215   
P7(OH) GLN 155 NE2     * 2.462       
P8(O) TRP147 NE1 
 
* 2.887 * 2.882 * 2.887   * 2.887 * 2.880 
P9(N) ASP 77 OD1 * 2.834 * 2.877 * 2.834 * 2.811 * 2.835S * 2.809 
P9(O) LYS 146  NZ 
 
  * 3.060   * 2.832   * 3.075 
P9(OXT) LYS146 NZ 
 
  * 2.791       * 3.127 
THR 143  OG1   * 2.617       * 2.625 
Total no of interactions 5  9  6  5  5  10  
Side chain interactions _  _  1  _  _  1  
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aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 









dbinit dcMD dbinit dcMD dbinit dcMD 
 
P1(N) 
GLU 63 OE1   * 2.746         
GLU 63 OE2 
 
  * 2.940   * 2.705   * 2.661 
TYR 59 OH   * 3.129         
P1(O) TYR 159 OH 
 
* 2.673   * 3.365   * 2.963 * 2.736 
P2(N) GLU 63  OE2 * 2.900 * 2.818 * 2.918   * 2.873   
P2(O) LYS 66 NZ 
 
* 2.940 * 2.893 * 2.885S   * 2.813   
 
P2(OG) 
GLU 63 OE1           * 2.601 
GLU 63 OE2           * 3.073 
P3(OD1) LYS 66 NZ           * 2.775 
P3(OE1) HIE 70 NE2       * 2.892     
P3(OD2) TYR 99 OH           * 2.723 
P5(O) GLN 155 NE2       * 2.804     
P5(NH1) THR 163 OG1       * 3.059     
 
P6(O) 
THR 73 OG1     * 3.336       
HIE 114 NE2           * 2.978 
ARG 97 NH2           * 2.810 
P6(OG) HIE 114 NE2       * 3.037     
P7(O) ARG 97 NH1     * 3.274   * 3.196   
 ARG 97 NH2           * 2.797 
P8(O) TRP147 NE1 
 
* 2.885   * 2.905   * 2.962 * 3.214 
LYS 146 NZ   * 2.994   * 2.879   * 2.882 
P8(OG1) LYS 146 NZ  
 




ASP 77 OD1           * 2.771 
P9(N) ASP 77 OD1 * 2.889 * 2.905 * 3.366   * 3.215 * 2.921 
P9(O) LYS 146 NZ 
 
  * 2.848       * 2.761 
P9(OXT) THR 143  OG1   * 2.695         
Total no of interactions 5  10  7  6  6  14  
 
Side chain interactions -  1 
 
   3  -  4  
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Appendix 2E. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 3I6G) complexes. 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 









dbinit dcMD dbinit dcMD dbinit dcMD 
P1(N) GLU 63 OE1   * 2.974   * 2.670   * 3.439 
GLU 63 OE2   * 2.806   * 3.092   * 2.695 
P1(O) TYR 159 OH * 2.698 * 2.705 * 2.799   * 2.739 * 2.819 
P2(N) GLU 63  OE1 * 2.698 * 2.799 
 
    * 2.842 * 2.754 
P2(O) LYS 66 NZ * 2.759 * 3.030         
P2(OG) GLU 63 OE1           * 2.606 
P3(N) TYR 99 OH   * 3.251     
 
    
P3(O) HIS 70 NE2   * 2.828       * 2.889 
P3(OE1) HIS 114 NE2       * 2.876     
ARG 97 NH1       * 2.854     
P3(OE2) ARG 97 NH1       * 3.363     
ARG 97 NH2       * 2.812     
P4(O) LYS 66 NZ     * 2.842       
P5(NH1) ALA 150 O       * 2.783     
GLN 155 OE1       * 2.845     
P6(OG) ARG 97 NH2 * 2.698           
THR 73 OG1     * 2.801       
P7(O) ARG 97 NH2           * 2.938 
P8(O) TRP147 NE1 * 2.698 * 2.828 * 2.891 * 2.927 * 3.019 * 2.866 
LYS 146 NZ           * 3.341 
ASP 77 OD1           * 2.670 
P9(N) ASP 77 OD1 * 2.698 * 3.003 * 2.904 * 3.080 * 2.885 * 2.821 
TYR 384 N       * 3.488     
P9(O) TYR 84 OH   * 3.311         
LYS 146 NZ   * 2.985 * 2.900       
P9(OXT) LYS 146 NZ   * 2.828       * 2.780 
TYR 84 OH   * 2.740   
 
      
THR 143 OG1   * 2.760   * 2.649     
Total no of interactions 6  14  6  12  4  12  
Side chain interactions 1  _  1  6  _  1  
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Appendix 2F. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 3TO2) complexes. 
 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance 












dbinit dcMD dbinit dcMD dbinit dcMD 
 
P1(N) 
GLU 63 OE1   * 2.691       * 2.689 
TYR 7 OH * 2.902.   
 
    
 
* 2.746   
TYR 159 OH * 2.169       * 3.374   
P1(O) TYR 7 OH     * 2.826     * 2.781 
P2(N) GLU 63 OE1 * 2.794   * 2.848   * 2.895   
GLU 63  OE2 * 2.725     * 2.704     
P2(O) LYS 66 NZ             
P2(OG) GLU 63 OE2           * 2.592 
P3(N) TYR 99 OH * 3.038           
P3(O) HIE 70 NE2     * 2.915       
TYR 159 OH           * 2.697 
P3(OD1) LYS 66 NZ           * 2.944 
LYS 66 NZ           * 2.943 
P3(OE1) HIE 114 NE2       * 2.897     
ARG 97 NH1       * 2.957     
P3(OE2) HIS 74 NE2       * 2.856     
HIS 70 NE2       * 2.763     
ARG 97 NH1       * 2.984     
P6(O) THR 73 OG1     * 3.379       
HIE 114 NE2   * 2.993         
ARG 97 NH1           * 2.964 
ARG 97 NH2           * 2.914 
ARG 97 NE   * 2.910         
P6(OG) ARG 97 NH1     * 3.074       
THR 73 OG1     * 2.969       
P7(O) ARG 97 NH2   * 2.810         
P8(O) TRP147 NE1 * 2.728 * 2.788 * 2.798   * 2.988 * 2.914 
P8(N) ASP 77 OD1   * 2.993         




P9(N) ASP 77 OD1         * 2.830   
P9(O) LYS 146  NZ 
 
* 2.915         * 2.832 
P9(OH) ASP 77 OD1       * 2.753     
ARG 97 NH2     * 2.884       
P9(OXT) LYS146 NZ 
 
* 3.287 * 2.899       * 2.876 
TYR 84 OH 
 
* 2.589 * 2.968   
 
      
THR 143  OG1 * 2.773 * 2.680         
Total no of interactions 11  9  8  7  5  11  
 
Side chain interactions 1  _ 
 
 3  6  _  3  
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Appendix 2G. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 4K7F) complexes. 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 









dbinit dcMD dbinit dcMD dbinit dcMD 
P1(N) GLU 62 OE1   * 2.739         
GLU 62 OE2 
 
  * 2.857       * 2.702 
P1(O) TYR 158 OH 
 
* 2.671 * 2.715 * 2.823   * 2.806 * 2.712 






* 2.864   * 2.883 
 
* 2.761 
GLU 62  OE2   * 2.779       * 3.447 
P2(OG) GLU 62 OE1           * 2.540 
P2(O) LYS 65 NZ 
 
* 2.582           
TYR 158 OH       * 2.975     
P2(N) GLU 62 OE2 * 3.067           
P2(SG) GLU 62 OE2   * 3.223         
P3(N) TYR 98 OH 
 
  * 2.978     
 
    
P3(O) HIE 69 NE2 * 2.956       * 3.089 * 3.059 
TYR 98 OH   * 2.955         
P3(OD1) ARG 96 NH2           * 3.540 
ARG 96 NH1           * 2.812 
P3(OD2) ARG 96 NH1           * 3.337 
ARG 96 NH2           * 2.756 
P3(OE1) HIE 113 NE2       * 2.813     
P3(OE2) ARG 96 NH1       * 2.781     
HIS 69 NE2       * 2.783     
P5(O) GLN 154 NE2   * 3.050         
P5(NE) GLN 154 O       * 2.908     
P5(NH2) GLN 154 O       * 3.551     
P6(O) THR 72 OG1   * 3.232         
ARG 96 NH1     * 2.925       
THR 72 OG1     * 3.230       
P7(O) TRP 146 NE1           * 2.970 
ARG 96 NH2     * 2.925       
P8(O) TRP146 NE1 
 
* 3.028 * 2.862 * 2.849 * 2.864 * 2.840   
P8(N) ASP 76 OD1 * 2.758           
P8(ND2) ASP 76 OD1   * 2.865         
P8(OG1) ASP 76 OD1   * 2.869        
 
 
 P9(N) ASP 76 OD1     * 2.834   * 2.892 * 2.859 
P9(O) LYS 145  NZ 
 
      * 2.832     
P9(OH) ARG 96 NE     * 2.917       
ARG 96 NH2     * 3.122       
P9(OXT) TYR 83 OH 
 
      
 
    * 2.886 
THR 142  OG1   * 2.675   * 2.740     
Total no of interactions 6  13  9  9  5  13  
 Side chain interactions 1  3 
 
 2  5    5  
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Appendix 2H. Hydrogen bonding interactions in HLA-A*0201 (PDB ID: 5SWQ) complexes. 
aDocked ZIKV E peptides, bInitial distance (after FlexPepDock) between the H-bond donor and acceptor; measured 
with the FindHBond tool in Chimera (H-bond constraints were relaxed by 0.4 and 20.0 Å degrees), cdistance between 










dbinit dcMD dbinit dcMD dbinit dcMD 
P1(N) GLU 63 OE1   * 2.741       * 2.911 
GLU 63 OE2 
 
  * 2.911   * 2.685   * 2.843 
P1(O) TYR 159 OH 
 
* 2.480 * 2.708 * 2.809   * 2.840   
TYR 7 OH           * 2.799 
P2(N) GLU 63  OE2   * 2.742   
 
      
P2(N) GLU 63 OE1 * 3.153       * 2.895   
P2(OG) GLU 63 OE1           * 2.701 
P2(O) LYS 66 NZ 
 
* 2.687           
TYR 99 OH           * 2.772 
P2(N) GLU 63 OE1     * 2.941       
P3(N) TYR 99 OH 
 
  * 3.044     
 
    
P3(OD1) HIS 70 NE2         * 2.704   
P4(O) LYS 66 NZ         * 2.920   
P5(NH1) ALA 150 O       * 2.858     
GLN 155 OE1       * 2.799     
P6(OG) HIE 70 NE2       * 3.112     
P7(O) ARG 97 NH1       * 3.378   * 2.891 
ARG 97 NH2           * 2.864 
P8(O) TRP147 NE1 
 
* 2.846 * 2.916 * 2.674 * 3.015 * 2.719 * 2.989 






         
P8(N) ASP 77 OD1 * 2.889           
P9(N) ASP 77 OD1   * 2.851   * 2.931 * 3.015   
P9(O) LYS 146  NZ 
 
  * 2.965     
 
    
THR 143 OG1  
 
         * 2.599 
P9(OH) ARG 97 NE     * 3.149       
ARG 97 NH2     * 2.961       
P9(OXT) THR 142  OG1   * 2.675         
Total no of interactions 6  9  5  7  6  9  
 
Side chain interactions _  _ 
 
 _  3  1  1  
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Figure 11.1. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0101; (C) Crystal complex of 
HLA-A*0101 with Influenza A virus (H1N1) peptide (cartoon representation); the complex obtained from docking or 
Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent 
energy minimization (in cyan): (A) TMNNKHWLV; (B) GLDFSDLYY; (C) CTELKLSDY (PDB ID: 4NQV). D: MHC I binding 
groove (F pocket) (cartoon representation colored in tan, model before minimization); distance 1 (d1) and distance 







Figure 11.2. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with Influenza A virus peptide (cartoon representation); the complex obtained from docking or Protein 
Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent energy 
minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) GILGFVFTL (PDB ID: 1OGA). Visualization with Chimera v. 





Figure 11.3. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex HLA-
A*0201 with transcriptional activator TAX peptide (cartoon representation); the complex obtained from docking or 
Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent 
energy minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) LLFGKPVYV (PDB ID: 2GIT). Visualization with 








Figure 11.4. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with melanoma peptide (cartoon representation); the complex obtained from docking or Protein Data 
Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent energy 
minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) LAGIGILTV (PDB ID: 2GTW). Visualization with Chimera v. 





Figure  11.5. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with melanoma peptide (cartoon representation); the complex obtained from docking or Protein Data 
Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent energy 
minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) ALGIGILTV (PDB ID: 2GTZ). Visualization with Chimera v. 







Figure  11.6. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with a peptide from membrane protein of SARS virus (cartoon representation); the complex obtained 
from docking or Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation 
and subsequent energy minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) GLMWLSYFV (PDB ID: 3I6G). 




Figure 11.7. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with membrane glycoprotein peptide (cartoon representation); the complex obtained from docking or 
Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent 
energy minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) LACFVLAAV (PDB ID: 3TO2). Visualization with 





Figure 11.8. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with Hepatitis B virus peptide (cartoon representation); the complex obtained from docking or Protein 
Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent energy 
minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) VCWGELMNL (PDB ID: 4K7F). Visualization with Chimera 





Figure  11.9. (A-B) E protein peptides from ZIKV in the binding groove of MHC I HLA-A*0201; (C) Crystal complex of 
HLA-A*0201 with NA231 influenza epitope (cartoon representation); the complex obtained from docking or Protein 
Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent energy 
minimization (in cyan): (A) MAEVRSYCY; (B) FSDLYYLTM; (C) CVNGSCFTV (PDB ID: 5SWQ). Visualization with Chimera 





Figure 11.10. (A-B) NS3 protein peptides from ZIKV in the binding groove of MHC I HLA-B*2705; (C) Crystal complex 
of HLA-B*2705 with Influenza A virus peptide (cartoon representation); the complex obtained from docking or 
Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent 
energy minimization (in cyan): (A) DIGAVALDY; (B) HSEVQLLAV; (C) SRYWAIRTR (PDB ID: 2BST). Visualization with 
Chimera v. 1.13 (Pettersen et al., 2004). 
 
 
Figure 11.11. (A-B) NS5 protein peptides from ZIKV in the binding groove of MHC I HLA-C*0801; (C) Crystal complex 
of HLA-C*0801 with Influenza A virus peptide (cartoon representation); the complex obtained from docking or 
Protein Data Bank (in tan) is superimposed with the complex obtained after the 10-ns MD simulation and subsequent 
energy minimization (in cyan): (A) MTTEDMLVV; (B) FTNLVVQLI; (C) GILGFVFTL (PDB ID: 4NT6). Visualization with 
Chimera v. 1.13 (Pettersen et al., 2004). 
 
 
                                                
 
 
 
 
